PRODUCT MONOGRAPH

PrTASIGNA®

(Nilotinib Capsules)

50 mg, 150 mg and 200 mg nilotinib (as nilotinib hydrochloride monohydrate)

Protein kinase inhibitor

Novartis Pharmaceuticals Canada Inc.
385, Bouchard Blvd.
Dorval, Quebec, H9S 1A9

Date of Preparation: December 4, 2006

Control No: 242015

Date of Revision: November 17, 2020

TASIGNA is a registered trademark
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3
  INDICATIONS AND CLINICAL USE ........................................................................ 3
  CONTRAINDICATIONS ........................................................................................... 4
  WARNINGS AND PRECAUTIONS ......................................................................... 5
  ADVERSE REACTIONS ............................................................................................ 15
  DRUG INTERACTIONS ............................................................................................ 24
  DOSAGE AND ADMINISTRATION ....................................................................... 33
  OVERDOSAGE ........................................................................................................ 42
  ACTION AND CLINICAL PHARMACOLOGY ...................................................... 42
  STORAGE AND STABILITY ................................................................................... 45
  SPECIAL HANDLING INSTRUCTIONS ................................................................. 45
  DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................... 46

PART II: SCIENTIFIC INFORMATION ....................................................................... 47
  PHARMACEUTICAL INFORMATION .................................................................... 48
  CLINICAL TRIALS ............................................................................................... 50
  DETAILED PHARMACOLOGY ........................................................................... 71
  TOXICOLOGY ....................................................................................................... 73
  REFERENCES ........................................................................................................ 78

PART III: CONSUMER INFORMATION ..................................................................... 81
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Pharmaceutical Form/Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Capsule 200 mg</td>
<td>Capsule content: Lactose monohydrate.</td>
</tr>
<tr>
<td></td>
<td>Capsule 150 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule 50 mg</td>
<td>For a complete listing see Dosage Forms,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

TASIGNA (nilotinib capsules) is indicated for:

- the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).

  Clinical effectiveness of TASIGNA in adults with newly diagnosed Ph+ CML-CP is based on major molecular response rate at 12 months and complete cytogenetic response rate by 12 months.

- the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.

  Clinical effectiveness of TASIGNA in pediatric patients with newly diagnosed Ph+ CML-CP is based on major molecular response by 12 cycles and complete cytogenetic response at 12 cycles.

- the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib.

  Clinical effectiveness of TASIGNA in adults with imatinib-resistant or -intolerant Ph+ CML-CP was based on the unconfirmed major cytogenetic and complete hematologic response rates.
Clinical effectiveness of TASIGNA in imatinib-resistant or -intolerant Ph+ CML-AP for adult patients was based on the confirmed hematologic response rates and the unconfirmed major cytogenetic response rates.

- the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.

Clinical effectiveness of TASIGNA in pediatric patients with imatinib-resistant or -intolerant Ph+ CML-CP was based on the MMR rate at 6 cycles.

No overall survival benefit has been demonstrated.

**Pediatrics:** The safety and efficacy of TASIGNA in pediatric patients with Ph+ CML-CP from 2 to less than 18 years of age have been established. There is no experience in pediatric patients below 2 years of age or in pediatric patients with Ph+ CML-AP or blast crisis (BC). The long-term effects of prolonged treatment with TASIGNA in pediatric patients are unknown (see **WARNINGS AND PRECAUTIONS**).

**Geriatrics (≥ 65 years of age):** Approximately 12% and 30% of subjects in the clinical studies (Phase III study (A2303) in newly diagnosed Ph+ CML-CP; and Phase II study (A2101) in resistant or -intolerant Ph+ CML-CP and CML-AP) were 65 years of age or older respectively. No major differences were observed for safety and efficacy in patients ≥ 65 years of age as compared to adults 18 to 65 years of age.

**CONTRAINDICATIONS**

Do not use in patients with a known long QTc prolongation or with a persistent QTc of >480 msec (See **WARNINGS AND PRECAUTIONS**).

Do not use in patients with uncorrectable hypokalemia or hypomagnesemia.

Do not use in patients with known hypersensitivity to nilotinib or to any of the excipients (for a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph).
WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- Sudden Cardiac Deaths (see Warnings and Precautions and Adverse Reactions)
- QT interval prolongation (see Warnings and Precautions, Drug Interactions, Food-effect and Monitoring and Laboratory Tests)
- Do not use in patients with uncorrectable hypokalemia or hypomagnesemia (see Warnings and Precautions)
- Ischemic heart disease, ischemic cerebrovascular events and peripheral arterial occlusive disease (PAOD), (in some rare cases, fatal) (see Warnings and Precautions and Monitoring and Laboratory Tests)
- Hepatotoxicity/ Hepatic failure (in some cases, fatal) (see Warnings and Precautions)
- Pancreatitis (see Warnings and Precautions)
- Myelosuppression (thrombocytopenia, neutropenia and anemia) (see Warnings and Precautions)

TASIGNA should only be prescribed by a qualified healthcare professional who is experienced in the use of antineoplastic therapy and in the treatment of chronic myeloid leukemia.

Treatment discontinuation in Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5) should be attempted only if the monitoring requirements using a quantitative diagnostic test validated with a sensitivity of at least MR4.5 (BCR-ABL/ABL ≤0.0032% IS) can be performed at the specified frequency (see Warnings and Precautions; Monitoring and Laboratory Tests). Discontinuation of TASIGNA therapy should be initiated by a physician experienced in the treatment of patients with CML.

Discontinuation of TASIGNA treatment to attempt treatment-free remission (TFR) phase in pediatric patients has not been assessed.

General

**BCR-ABL Mutations** : The T315I mutation confers a high level of resistance to nilotinib and most tyrosine kinase inhibitors based on *in vitro* and clinical data.

**Carcinogenesis and Mutagenesis**

In the 2-year rat carcinogenicity study conducted orally at TASIGNA at 5, 15, and 40 mg/kg/day, there was a non-statistically significant increased incidence of uterine hemangiosarcoma, adenocarcinoma and squamous cell carcinoma and an increase in follicular cell adenoma in the thyroid gland (barely reaching statistical significance). Given that the incidence of thyroid follicular cell adenoma and uterine adenocarcinoma were within the historical control range, the data do not clearly indicate that TASIGNA is carcinogenic in rats. Exposures (in terms of AUC) at the highest dose level represented approximately 2x to 3x human daily steady state exposure at the dose of 800 mg/day. TASIGNA is not mutagenic (see TOXICOLOGY).
In the 26-week Tg.rasH2 mouse carcinogenicity study, in which nilotinib was administered at 30, 100 and 300 mg/kg/day, skin papillomas/carcinomas were detected at 300 mg/kg, representing approximately 30 to 40 times (based on AUC) the human exposure at the maximum approved dose of 800 mg/day (administered as 400 mg twice daily). The No-Observed-Effect-Level for the skin neoplastic lesions was 100 mg/kg/day, representing approximately 10 to 20 times the human exposure at the maximum approved dose of 800 mg/day (administered as 400 mg twice daily).

The relevance of the findings from the rat and mouse carcinogenicity studies for humans is not known at this time.

**Cardiovascular**

**Sudden Cardiac Deaths:** In clinical trials, 19 cases of sudden cardiac death have been reported out of 11,351 patients receiving TASIGNA (uncommon frequency of 0.17%). Of the 19 cases, 13 documented cases had a past medical history of cardiac disease or significant cardiac risk factors for sudden cardiac death. In 4 of the 19 cases of sudden cardiac death, patients had no prior medical history of cardiac disease. Comorbidities in addition to the underlying malignancy were also frequently present as concomitant medications. Ventricular repolarization abnormalities may have been contributory factors. No cases of sudden cardiac deaths have been reported in any treatment group in the newly diagnosed Ph+ CML-CP Phase III study (A2303). Based on post-marketing exposure in patient-years, the estimated reporting rate for spontaneous reports of sudden death is 0.02% per patient-year.

**QT Prolongation:** *In vitro* data indicate that nilotinib has the potential to prolong cardiac ventricular repolarization (QT interval).

In the Phase III study (A2303) in newly diagnosed Ph+ CML-CP patients, the maximum QTcF mean increase from baseline was 12.3 msec in the nilotinib 300 mg twice daily arm (two-sided 90% Upper CI: 14.4) and 12.9 msec in the nilotinib 400 mg twice daily arm (two-sided 90% Upper CI: 15.1). At the recommended dose of 300 mg twice daily no patient had an absolute QTcF of >480 msec and no events of Torsades de Pointes were observed in this trial. One patient in the 400 mg twice daily arm had an absolute QTcF of >480 msec. Thirty-two (32) patients (11.5%) in nilotinib 300 mg twice daily treatment group and 40 patients (14.4%) in nilotinib 400 mg twice daily treatment group had absolute QTcF >450 msec. QTcF increase from baseline that exceeded 60 msec was observed in 5 patients while on treatment drug (one in the TASIGNA 300 mg twice daily treatment group and four in the TASIGNA 400 mg twice daily treatment group).

In the Phase II study (A2101) in imatinib-resistant or -intolerant CML patients in CP and AP, treated with nilotinib 400 mg twice daily, the change from baseline in mean time-averaged QTcF interval at steady-state was 5 msec and 8 msec, respectively. The maximum QTcF mean increase from baseline was 6.8 msec (two-sided 90% Upper CI: 8.4) and 13.4 msec (two-sided 90% Upper CI: 17.2) respectively. QTcF of >500 msec was observed in 4 (1.2%) of CML-CP patients. QTcF > 60 msec increase from baseline was observed in the combined CML-CP and –AP patient populations (CML-CP 8 (2.5%) and CML-AP 11 (8%).
In a healthy volunteer study (A2119), peak plasma concentrations were 26% lower than in the clinical study in CML patients. The maximum mean placebo-adjusted QTcF increase from baseline was 18 msec (1-sided 95% Upper CI: 26 msec). In addition, no clinically relevant arrhythmias were observed during the conduct of the trial. In particular, no episodes of Torsades de Pointes (either transient or sustained) were observed.

Clinically meaningful prolongation of the QT interval may occur when TASIGNA is inappropriately taken with food, and/or strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT; therefore, concomitant administration should be avoided (see Drug-Food Interactions and Drug-Drug Interactions).

The presence of hypokalemia and hypomagnesemia may place patients at risk of developing QT prolongation (see CONTRAINDICATIONS).

TASIGNA should be avoided in patients who are at significant risk of developing prolongation of QTc interval, such as: patients taking anti-arrhythmic medicines or other drugs that may lead to QT prolongation, and cumulative high-dose anthracycline therapy. Hypokalemia or hypomagnesemia must be corrected prior to TASIGNA administration (See Drug-Drug Interactions and DOSAGE AND ADMINISTRATION).

TASIGNA should be used with caution in patients with uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure (CHF), unstable angina or clinically significant bradycardia.

Other Cardiovascular Disorders: In clinical studies, newly diagnosed Ph+ CML-CP and imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients with any of the following uncontrolled or significant cardiac disease were excluded: recent myocardial infarction, CHF, unstable angina, or clinically significant bradycardia. Imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients with complete left bundle branch block and/or right bundle branch block, with left anterior hemiblock, or with bifascicular block were excluded from the study. Newly diagnosed Ph+ CML-CP patients with complete left bundle branch block were also excluded. ECG and cardiac enzyme monitoring were conducted in patients throughout the studies.

In newly diagnosed Ph+ CML-CP, left ventricular ejection fraction (LVEF) was assessed by echocardiography at baseline (within 14 days prior to the initial dose of nilotinib) in all patients. LVEF assessment was repeated in these patients on a regular basis and as clinically indicated thereafter. No patients in any treatment groups had a LVEF <45% during treatment. Also, there were no patients with 15% or greater decrease from baseline in LVEF.

In imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients, LVEF was assessed by echocardiography or MUGA scan at baseline (within 14 days prior to the initial dose of nilotinib) in 49/438 patients. LVEF assessment was repeated in these patients as clinically indicated thereafter, and at the time of study completion. There was no clinically significant change in LVEF from baseline in the assessed patients.
Cardiovascular adverse reactions have been observed in patients in the TASIGNA clinical studies at the recommended doses including cardiac failure observed in <1% of patients with imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP, and with newly diagnosed Ph+ CML-CP. In a Phase III study (A2303) in newly diagnosed Ph+ CML patients, with a median time on therapy of 60.5 months in the clinical trial, cases of cardiovascular events included ischemic heart disease-related events (5.0% and 9.4% in the nilotinib 300 mg and 400 mg twice daily groups respectively, and 2.5% in the imatinib arm), peripheral arterial occlusive disease (3.6% and 2.9% in the nilotinib 300 mg and 400 mg twice daily groups respectively, and 0% in the imatinib arm), and ischemic cerebrovascular events (1.4% and 3.2% in the nilotinib 300 mg and 400 mg twice daily groups respectively, and 0.7% in the imatinib arm).

Peripheral arterial occlusive disease, ischemic heart disease and ischemic cerebrovascular events include events such as femoral artery stenosis, coronary artery stenosis, cerebrovascular accident, vascular graft occlusion, arterial stenosis limb and carotid artery stenosis. Peripheral arterial occlusive disease can be severe, rapidly evolving and may affect more than one site. Peripheral arterial occlusive disease might require repeated revascularization procedures and can result in complications that may be serious such as limb necrosis and amputations. Most of the patients who developed cardiovascular adverse reactions had pre-existing documented cardiovascular disease or risk factors for atherosclerotic-related disease.

Of the 365 patients treated with TASIGNA, who had no documented pre-existing risk factors for cardiovascular disease, 19 patients (5%) experienced atherosclerotic-related events. Since it is not known whether TASIGNA caused or exacerbated these conditions, patients should be monitored during treatment with TASIGNA for signs of atherosclerotic-related conditions and actively managed during TASIGNA therapy according to standard guidelines. If acute signs or symptoms of cardiovascular events occur, advise patients to seek immediate medical attention. Administer with caution in patients with pre-existing risk factors for atherosclerosis (See Monitoring and Laboratory Tests, DOSAGE AND ADMINISTRATION/Dose Adjustments or Modifications, ADVERSE REACTIONS and Post-Market Adverse Reactions).

**Endocrine and Metabolism**

**Diabetes/hyperglycemia:** New-onset diabetes/hyperglycemia were reported with a common frequency (4.8%) in CML patients in completed clinical trials. In addition, cases of exacerbated diabetes have been reported from post-marketing experience (see ADVERSE REACTIONS).

**Fluid retention:** Medically severe forms of drug-related fluid retention such as Grade 3 or 4 pleural effusion, pulmonary edema, and pericardial effusion were reported with an uncommon frequency (0.1 to 1%) observed in a Phase III study of newly diagnosed Ph+ CML-CP patients. Similar events were observed in post-marketing reports. Unexpected, rapid weight gain should be carefully investigated. If signs or symptoms of severe fluid retention appear during treatment with TASIGNA, the etiology should be evaluated and patients treated accordingly (see Monitoring and Laboratory Tests, DOSAGE AND ADMINISTRATION/ Dose Adjustments or Modifications).
Hematologic

Myelosuppression: Treatment with TASIGNA is often associated with thrombocytopenia, neutropenia and anemia (NCI CTC Grade 3/4). The occurrence is more frequent in patients with imatinib-resistant or -intolerant CML and in particular in patients with CML-AP. Complete blood counts should be performed every two weeks for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding TASIGNA temporarily or reducing the dose (see DOSAGE AND ADMINISTRATION).

Hemorrhage

Gastrointestinal and Central Nervous System (CNS) hemorrhage were reported in 1% and <1% of imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients, respectively. In newly diagnosed Ph+ CML-CP, gastrointestinal hemorrhage, regardless of causality, was reported in 3% in the patients receiving TASIGNA 300 mg twice daily and in 5% in the patients receiving TASIGNA 400 mg twice daily. CNS hemorrhage, regardless of causality, was reported in <1% of the newly diagnosed Ph+ CML-CP patients receiving TASIGNA 300 mg and in patients receiving TASIGNA 400 mg twice daily (See ADVERSE REACTIONS).

Hepatic/Biliary and Pancreatic

Hepatotoxicity/Hyperbilirubinemia: TASIGNA may result in elevation of bilirubin due to competitive inhibition of Uridine-Diphosphate-Glucuronyl Transferase (UGT1A1) and in elevation of alanine transaminase (AST), aspartate aminotransferase (ALT) and alkaline phosphatase (see Drug-Drug Interactions and ADVERSE REACTIONS). Patients taking TASIGNA who may be predisposed to or who may have Gilbert’s syndrome may have a higher risk of unconjugated hyperbilirubinemia. This may also occur in patients who are taking drugs known to inhibit UGT1A1.

Pediatric population: Laboratory abnormalities of mild to moderate transient elevations of aminotransferases and total bilirubin have been observed in children at a higher frequency than in adults, indicating a higher risk of hepatotoxicity in the pediatric population (see ADVERSE REACTIONS, Safety of TASIGNA in Pediatric Patients with Newly Diagnosed or Resistant/Intolerant Ph+ CML-CP). If clinically significant hepatotoxicity develops, consider dose modifications (see DOSAGE AND ADMINISTRATION).

Hepatic Failure: Twenty five cases of hepatic failure were reported in CML patients. Five of these were fatal including one case with no previous hepatic impairment. There were 29 cases of ascites reported in pooled clinical trials data which included all adverse events regardless of causality and the patient population. Three cases of hepatic steatosis and 2 cases of hepatic necrosis were reported in all clinical trial patients. One of those fatal cases which satisfied Hy’s Law was hepato-renal syndrome and fulminant hepatitis reported in a 23 year old male CML patient who had received 4 months of treatment with TASIGNA. Two cases of cytolytic hepatitis were reported in newly diagnosed Ph+ CML-CP patients. If clinically significant hepatotoxicity develops, consider dose modifications (see DOSAGE AND ADMINISTRATION).
**Elevated Serum Lipase/Amylase:** Grade 3/4 elevation in serum lipase and amylase have been observed. Few of these elevations were associated with abdominal pain or pancreatitis. There were 5 cases (1.1%) of pancreatitis reported in imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients (N= 458). In newly diagnosed Ph+ CML-CP, 5 (1.8%) and 8 (2.9%) cases of pancreatitis were reported in patients receiving TASIGNA 300 mg twice daily (N=279), and 400 mg twice daily (N=277) respectively. Caution is recommended in patients with previous history of pancreatitis. In case lipase elevations are accompanied by abdominal symptoms, doses should be interrupted and appropriate diagnostics should be considered in order to rule out pancreatitis (see DOSAGE AND ADMINISTRATION).

**Immune**

Six cases of vasculitis (including 1 cerebral) have been reported in pooled clinical trials data which included all adverse events regardless of causality and the patient population (see ADVERSE REACTIONS).

**Hepatitis B virus reactivation:** Reactivation of hepatitis B virus (HBV) has occurred in patients who are chronic carriers of this virus after receiving a BCR-ABL tyrosine kinase inhibitor (TKI), including TASIGNA. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or death.

Patients should be tested for HBV infection before initiating treatment with TASIGNA. Patients currently on TASIGNA should have baseline testing for HBV infection in order to identify chronic carriers of the virus. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive HBV serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with TASIGNA should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.

**Musculoskeletal**

Several cases of possible rhabdomyolysis, and some with concomitant elevations in serum creatinine, creatine kinase, creatine phosphokinase and hepatic transaminases, have been reported (unknown frequency). Several of these cases had pre-existing risk factors and/or were receiving concomitant medications known to be associated with this adverse event (see ADVERSE REACTIONS).

**Peri-Operative Considerations**

**Total gastrectomy:** The bioavailability of nilotinib was shown to be reduced in patients administered 400 mg bid TASIGNA with total gastrectomy versus non-gastrectomized patients (see Pharmacokinetics section). More frequent follow-up of adult and pediatric patients should be considered.
Renal
Acute renal failure (including a fatality) has been reported in 4 CML patients (uncommon frequency).

Respiratory
Four cases of interstitial lung disease (Grade 3/4) have been reported (uncommon frequency) in CML patients.

Sensitivity/Intolerance
Since the capsules contain lactose, TASIGNA is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or of glucose-galactose malabsorption.

Sexual Function/Reproduction
Fertility: The effect of TASIGNA on male and female fertility in humans is not known. Increased post-implantation loss was observed in both the fertility study, with the treatment of both female and male rats, and in the embryotoxicity study with the treatment of female rabbits (see TOXICOLOGY, Reproductive toxicity studies). Sexually active male or female patients taking TASIGNA should use highly effective contraception. Prior to initiating TASIGNA therapy, physicians should advise and counsel their patients as appropriate (see WARNINGS AND PRECAUTIONS, Females of childbearing potential and Male patients).

Tumour Lysis Syndrome
Cases of tumor lysis syndrome have been reported in patients treated with TASIGNA in pooled clinical trials. For monitoring recommendations see DOSAGE AND ADMINISTRATION.

Special Populations
Renal Impairment
Clinical studies have not been performed in patients with impaired renal function. Clinical studies have excluded patients with serum creatinine concentration >1.5 times the upper limit of the normal range.

TASIGNA and its metabolites are not renally excreted (See Pharmacokinetics).

Due to the potential for tumour lysis syndrome in patients treated with TASIGNA, patients with decreased renal function may be at increased risk (See MONITORING AND LABORATORY TESTS and DOSAGE AND ADMINISTRATION).

Hepatic impairment
Hepatic impairment has an effect on the pharmacokinetics of TASIGNA. Single dose administration of TASIGNA 200 mg in adults resulted in increases in AUC of 35%, 35% and 56% in subjects with mild, moderate and severe hepatic impairment, respectively compared to a control group of subjects with normal hepatic function. The steady-state Cmax of TASIGNA will...
likely to be increased by up to approximately 29% in subjects with hepatic impairment. Clinical studies have excluded patients with ALT and/or AST >2.5 (or >5, if related to disease) times the upper limit of the normal range and/or total bilirubin >1.5 times the upper limit of the normal range. Metabolism of nilotinib is mainly hepatic. TASIGNA should be used with caution and careful clinical monitoring (including close monitoring of the QTc interval) in patients with hepatic impairment (see DOSAGE AND ADMINISTRATION).

_Gilbert's syndrome:_ Due to a polymorphism in the enzyme UGT1A1 in patients who may be predisposed to Gilbert's syndrome, or in patients with Gilbert's syndrome, a higher risk unconjugated hyperbilirubinemia with nilotinib can occur, but is clinically benign and potentially persistent. No specific medical intervention is warranted (see DOSAGE AND ADMINISTRATION).

**Pregnant Women**

There are limited data on the use of TASIGNA in pregnant women. TASIGNA should not be used during pregnancy. There have been post-market reports of serious adverse events (spontaneous abortions, premature delivery, fetal abnormalities and/or deaths) from women who have taken TASIGNA during pregnancy (see ADVERSE REACTIONS, Post Market Adverse Reactions, Pregnancy, Puerperium and Perinatal conditions, and Congenital, Familiar and Genetic Disorders).

Studies in pregnant rats and rabbits showed maternal and embryo-fetal toxicity and lethality at exposures to nilotinib comparable to the human exposure (see TOXICOLOGY, Reproductive toxicity studies). Nilotinib and/or its metabolites showed placenta transfer to the fetus which may account for the incidence of embryolethal and embryotoxicity (see DETAILED PHARMACOLOGY, Animal pharmacokinetics).

Therefore, pregnant women must be informed of the potential harm to the fetus prior to initiation of TASIGNA therapy. If a patient becomes pregnant while taking TASIGNA, the benefits of therapy versus the potential risks of the fetus should be evaluated by the physician and the treatment options should be discussed with the patients.

If a woman who is being treated with TASIGNA is considering pregnancy, treatment discontinuation may be envisaged based on the eligibility criteria for discontinuing treatment as described in sections on DOSAGE AND ADMINISTRATION There is limited data on pregnancies in patients while attempting TFR. If a pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with TASIGNA during the pregnancy (see sections on DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS, Pregnant Women).

**Nursing Women**

Animal studies demonstrate that nilotinib is excreted into breast milk of rats (see TOXICOLOGY, Animal pharmacokinetics). Women taking TASIGNA should not breast-feed while taking TASIGNA and for 2 weeks after the last dose, as a risk to the infant cannot be excluded.
**Male Patients**
It is not known if nilotinib is present in semen. Sexually active male patients must always use highly effective contraception during the treatment and for at least 4 weeks after ending TASIGNA therapy. There are post-market reports for pregnancies occurring in the female partners of male patients who were receiving TASIGNA. Outcomes include spontaneous abortions, premature delivery and fetal abnormalities (see ADVERSE REACTIONS, Post-Market Adverse Reactions).

Therefore, male patients must be advised to inform their female sexual partners that they are taking TASIGNA. Male patients should also advise their female partners of the potential serious risks to a developing fetus should pregnancy occur during her partner’s treatment with TASIGNA.

**Females of Childbearing Potential**
Females of child-bearing potential are all females who are menstruating, or who are physiologically capable of becoming pregnant.

TASIGNA can cause fetal harm should pregnancy occur (See WARNINGS AND PRECAUTIONS, Pregnant Women). Female of childbearing potential must be advised to use highly effective method of contraception while receiving TASIGNA and at least 4 weeks after ending treatment. Highly effective contraception is a method of birth control which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. If a patient becomes pregnant while taking TASIGNA, the benefits of therapy versus the potential risks of the fetus should be evaluated by the physician and the treatment options should be discussed with the patients.

**Pediatric Patients (2-17 years of age)**
There is no experience with TASIGNA in pediatric patients below 2 years of age.

The long-term effects of prolonged treatment with TASIGNA in pediatric patients are unknown. There have been case reports of growth retardation in pediatric patients treated with TASIGNA. Inform pediatric patients and their caregivers of the possibility of developing growth abnormalities (see ADVERSE REACTIONS, Growth Retardation in Pediatric Patients). Growth and development in pediatric patients receiving TASIGNA should be closely monitored (see Monitoring and Laboratory Tests).

Discontinuation of TASIGNA treatment to attempt the treatment-free remission phase in pediatric patients has not been assessed.

**Geriatrics (≥ 65 years of age)**
Approximately 12% and 30% of subjects in the clinical studies (Phase III study (A2303) in newly diagnosed Ph+ CML-CP; and Phase II study (A2101) in resistant or -intolerant Ph+ CML-CP and CML-AP) were 65 years of age or older respectively. No major differences were observed for safety and efficacy in patients ≥65 years of age as compared to adults 18 to 65 years of age.
Monitoring and Laboratory Tests

Complete blood counts should be performed every two weeks for the first 2 months and then monthly thereafter or as clinically indicated (See WARNINGS AND PRECAUTIONS).

Electrocardiograms (ECGs) should be obtained before treatment, seven days after initiation and periodically thereafter, as well as following dose adjustments (See WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Liver function, (transaminases, total bilirubin and alkaline phosphatase) needs to be monitored before treatment, frequently during treatment, following dose adjustments or as clinically indicated (see WARNINGS AND PRECAUTIONS; DOSAGE AND ADMINISTRATION; TOXICOLOGY).

Serum electrolytes (including phosphorus, potassium and magnesium) as well as serum lipase/amylase, fasting glucose, HbA1C, creatine kinase (CPK), uric acid, creatinine, and lactate dehydrogenase (LDH) levels need to be monitored before treatment and frequently during treatment with TASIGNA and as clinically indicated (See WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Patients with symptomatic PAOD should be monitored and actively managed during TASIGNA therapy according to standard guidelines.

Adequate hydration should be maintained if tumor lysis syndrome is considered a substantial risk.

In a Phase III study in newly diagnosed CML patients, 1.1% of the patients treated with 400 mg TASIGNA twice a day, had a Grade 3/4 elevation in total serum cholesterol; however, there were no Grade 3/4 elevations in the group receiving the recommended dose of 300 mg twice a day (See ADVERSE REACTIONS/Investigations). It is recommended that the lipid profiles be determined before initiating treatment with TASIGNA, assessed at month 3 and 6 after initiating therapy, and at least yearly during therapy (See ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION/ Dose Adjustments or Modifications). If test results warrant therapy, physicians should follow their local standards of practice and treatment guidelines. If lipid lowering agents are needed, please refer to Drug-Drug Interactions section before starting treatment.

Patients should be weighed and monitored regularly for signs and symptoms of fluid retention (see WARNINGS AND PRECAUTIONS). If therapeutic measures include the use of medications, please refer to Drug-Drug Interactions section before starting treatment.

Growth and physical development should be monitored using standard parameters in pediatric patients receiving TASIGNA.
Monitoring of BCR-ABL transcript levels in patients who discontinued TASIGNA:
Monitoring of BCR-ABL transcript levels in patients eligible for treatment discontinuation, during TFR and re-treatment, must be performed with a quantitative diagnostic test validated to measure molecular response levels with a sensitivity of at least MR4.5 ($\text{BCR-ABL}/\text{ABL} \leq 0.0032\%$ IS).

In patients who discontinue TASIGNA therapy, monitor complete blood count (CBC) and BCR-ABL transcript levels monthly for one year, then every 6 weeks for the second year, and every 12 weeks thereafter during treatment discontinuation.

Newly diagnosed patients must reinitiate TASIGNA therapy within 4 weeks of a loss of Major Molecular Response (MMR, corresponding to MR3.0 or $\text{BCR-ABL}/\text{ABL} \leq 0.1\%$ IS).

Patients resistant or intolerant to prior treatment which included imatinib must reinitiate TASIGNA therapy within 4 weeks of a loss of MMR or confirmed loss of MR4.0 (two consecutive measures separated by at least 4 weeks showing loss of MR4.0, corresponding to $\text{BCR-ABL}/\text{ABL} \leq 0.01\%$ IS).

For patients who fail to achieve MMR after three months of treatment re-initiation, BCR-ABL kinase domain mutation testing should be performed.

Monitoring of BCR-ABL Transcript Levels in Patients who have Reinitiated Therapy after Loss of Molecular Response: Monitor CBC and BCR-ABL transcript levels in patients who reinitiate therapy due to loss of molecular response quantitation monthly until MMR is re-established and every 12 weeks thereafter.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Sudden Cardiac Deaths
From clinical trials including the Phase II study (A2101), the Expanded Access Program, and the Compassionate Use Program, 19 cases of sudden cardiac deaths have been reported out of 11,351 patients receiving TASIGNA (uncommon frequency of 0.17%). Of the 19 cases, 13 documented cases had a past medical history of cardiac disease or significant cardiac risk factors for sudden cardiac death. In 4 of the 19 cases of sudden cardiac death, patients had no prior medical history of cardiac disease. Comorbidities in addition to the underlying malignancy were also frequently present as were concomitant medications. Ventricular repolarization abnormalities may have been contributory factors. No cases of sudden cardiac deaths have been reported in any treatment group in the newly diagnosed Ph+ CML-CP Phase III study.

Clinical Trial Adverse Drug Reactions

Summary of the safety profile
The TASIGNA safety profile described below is based on data from adult patients with newly diagnosed Ph+ CML-CP in a randomized, open label, active comparator-controlled Phase-III trial.
and adult patients with resistant or intolerant Ph+ CML-CP and CML-AP which served as a basis for the market authorized indications (see Table 1 and INDICATIONS AND CLINICAL USE). Safety information from two TASIGNA treatment discontinuation studies (I2201 and A2408) is also provided.

**In adult patients with newly diagnosed Ph+ CML-CP**

The data reported below reflect exposure to TASIGNA from a randomized Phase III study (A2303) in adult patients with newly diagnosed Ph+ CML in chronic phase (CP) treated at the recommended dose of TASIGNA 300 mg twice daily (N=279), with a median time on treatment of 60.5 months (range 0.1 – 70.8 months). Among the patients with newly diagnosed Ph+ CML-CP treated with TASIGNA at 400 mg twice daily (N=277), the median time on treatment was 60.7 months (range 0.2 – 71.8 months).

The very common (≥10%) non-hematologic adverse drug reactions (ADRs) were rash, pruritus, headache, nausea, alopecia, myalgia, and fatigue in the TASIGNA 300 mg twice daily group and 400 mg twice daily group. Most of these ADRs were mild to moderate in severity (Grade 1 or 2). Upper abdominal pain was very frequent in the 300 mg twice daily group and less frequent in the 400 mg twice daily group, whereas arthralgia and dry skin were very frequent in the 400 mg twice daily group and less frequent in the 300 mg twice daily group.

Diarrhea, constipation, muscle spasms, vomiting, abdominal pain, peripheral oedema, dyspepsia, and asthenia were less frequent (< 10% and ≥ 5%) in the TASIGNA 300 mg twice daily group and 400 mg twice daily group. They were mild to moderate severity, manageable and generally did not require dose reduction. In addition, erythema, and bone pain were less frequent (< 10% and ≥ 5%) in the 300 mg twice daily group whereas pain in the extremity was observed less frequently (< 10% and ≥ 5%) in the 400 mg twice daily group.

Pleural and pericardial effusions occurred in <1% of patients, receiving TASIGNA 300 mg twice daily and TASIGNA 400 mg twice daily. Grade 3 or 4 pleural effusion occurred in a patient receiving TASIGNA 300 mg twice daily.

Gastrointestinal hemorrhage, regardless of causality, was reported in 3% in patients receiving TASIGNA 300 mg twice daily and in 5% patients receiving TASIGNA 400 mg twice daily.

The maximum QTcF mean increase from baseline in the TASIGNA 300 mg twice daily group was 12.3-msec (two-sided 90% Upper CI: 14.4) and the maximum QTcF mean increase from baseline in the TASIGNA 400 mg twice daily group was 12.9-msec (two-sided 90% Upper CI: 15.1).

No patient had an absolute QTcF of >500 msec while on treatment drug in any of the TASIGNA treatment groups and no events of Torsades de Pointes were observed. One patient in the 400 mg twice daily arm had an absolute QTcF of >480 msec. QTcF increase from baseline that exceeds 60 msec was observed in 5 patients while on TASIGNA (one in the TASIGNA 300 mg twice daily treatment group and four in the TASIGNA 400 mg twice daily treatment group). No patients in any treatment group had a LVEF <45% during treatment. Also, there were no patients with 15% or greater decrease from baseline in LVEF.
No sudden cardiac deaths have been reported in any treatment group.

Hematologic ADRs include myelosuppression in patients receiving TASIGNA 300 mg twice daily and 400 mg twice daily respectively: thrombocytopenia (18%; 20%), neutropenia (15%; 11%), and anemia (8%; 9%). Biochemistry ADRs in patients receiving TASIGNA 300 mg twice daily and 400 mg twice daily, respectively include: alanine aminotransferase increased (24%; 29%), hyperbilirubinemia (17%; 17%), aspartate aminotransferase increased (12%; 15%), lipase increased (11%; 10%), blood bilirubin increased (10%; 14%), hyperglycemia (4%; 5%), hypercholesterolemia (3%; 6%), and hypertriglyceridemia (<1%; 1%). See Table 2 for Grade 3/4 laboratory abnormalities.

Discontinuation due to adverse drug reactions was observed in 10% of patients receiving TASIGNA 300 mg twice daily and in 17% of patients receiving TASIGNA 400 mg twice daily.

In adult patients with resistant or intolerant Ph+ CML-CP and CML-AP
The data reported below reflect exposure to TASIGNA in 458 adult patients with Ph+ CML-CP and CML-AP resistant to or intolerant to at least one prior therapy including imatinib (321 CML-CP patients and 137 CML-AP patients, respectively) in an open-label multicenter study. Patients were treated at the recommended dose of 400 mg twice daily.

Non-hematologic adverse drug reactions (ADRs) reported with very common frequency (≥10% in the combined CML-CP and CML-AP patient populations) were rash, pruritus, nausea, fatigue, headache, constipation and diarrhea, vomiting and myalgia. Most of these ADRs were mild to moderate in severity. Alopecia, muscle spasms, decreased appetite, arthralgia, bone pain, abdominal pain, peripheral oedema and asthenia were observed less frequently (<10% and ≥5%) and have been of mild to moderate severity (Grade 1 or 2).

Pleural and pericardial effusions as well as complications of fluid retention occurred in <1% of patients receiving TASIGNA.

Cardiac failure was observed in <1% of patients. QTcF exceeding 500 msec was observed in this study in 4 patients (< 1%). No episodes of Torsades de Pointes (transient or sustained) were observed.

Gastrointestinal and CNS hemorrhage was reported in 1% and <1% of patients, respectively.

Hematologic ADRs include myelosuppression: thrombocytopenia (31%), neutropenia (17%), and anemia (14%). See Table 2 for Grade 3/4 laboratory abnormalities.

Discontinuation due to adverse drug reactions was observed in 16% of CP and 10% of AP patients.

Most Frequently Reported Adverse Drug Reactions
Non-hematologic ADRs (excluding laboratory abnormalities) that were reported in at least 5% of the adult patients in any of the TASIGNA clinical studies that serve as a basis for the listed indications are shown in Table 1. These are ranked under heading of frequency, the most frequent first. Within each frequency grouping adverse drug reactions are presented in order of decreasing seriousness. In addition the corresponding frequency category for each adverse drug reaction is
based on the following convention: very common (≥ 10%) or common (≥ 1% to < 10%). The frequency is based on the highest for any TASIGNA group in the two studies, using one decimal precision for percentages.

Table 1  Most Frequently Reported Non-hematologic Adverse Drug Reactions (≥ 5% in any adult TASIGNA Group)
## Newly Diagnosed Ph+ CML-CP
### 60 month analysis

<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 300 mg twice daily</th>
<th>TASIGNA 400 mg twice daily</th>
<th>GLEEVEC® 400 mg once daily</th>
<th>TASIGNA 300 mg twice daily</th>
<th>TASIGNA 400 mg twice daily</th>
<th>GLEEVEC® 400 mg once daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL Grades (%)</td>
<td>N=279 %</td>
<td>N=277 %</td>
<td>N=280 %</td>
<td>N=279 %</td>
<td>N=277 %</td>
<td>N=280 %</td>
</tr>
<tr>
<td>Grade 3/4 (%)</td>
<td>0 %</td>
<td>0 %</td>
<td>0 %</td>
<td>0 %</td>
<td>0 %</td>
<td>0 %</td>
</tr>
</tbody>
</table>

## Resistant or Intolerant Ph+ CML-CP and CML-AP
### 24-month analysis

<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 400 mg twice daily</th>
</tr>
</thead>
</table>

## System Organ Class

### Metabolism and nutrition disorders
- **Decreased appetite**: 4 / 4 / 3 / 0 / 0 / 8 / <1 / <1 / 0

### Nervous system disorders
- **Headache**: 16 / 22 / 10 / 2 / 1 / <1 / 15 / 1 / 2 / <1

### Gastrointestinal disorders
- **Nausea**: 14 / 21 / 35 / <1 / 1 / <1 / 20 / <1 / <1 / <1
- **Constipation**: 10 / 7 / 3 / 0 / <1 / 0 / 12 / <1 / <1 / 0
- **Diarrhea**: 9 / 7 / 31 / <1 / 0 / 3 / 11 / 2 / 2 / <1
- **Vomiting**: 6 / 9 / 19 / 0 / 1 / 0 / 10 / <1 / <1 / 0
- **Abdominal pain upper**: 10 / 9 / 8 / 1 / 0 / <1 / 5 / <1 / <1 / 0
- **Abdominal pain**: 6 / 6 / 4 / 0 / <1 / 0 / 6 / <1 / <1 / <1
- **Dyspepsia**: 5 / 5 / 6 / 0 / <1 / 0 / 3 / 0 / 0 / 0

### Skin and subcutaneous tissue disorders
- **Rash**: 33 / 39 / 14 / <1 / 3 / 2 / 28 / 1 / 2 / 0
- **Pruritus**: 18 / 16 / 5 / <1 / <1 / 0 / 24 / <1 / <1 / 0
- **Alopecia**: 10 / 14 / 6 / 0 / 0 / 0 / 9 / 0 / 0 / 0
<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>12</th>
<th>5</th>
<th>0</th>
<th>0</th>
<th>0</th>
<th>5</th>
<th>0</th>
<th>0</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry Skin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema</td>
<td>3</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Myalgia</td>
<td>10</td>
<td>12</td>
<td>13</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>10</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>8</td>
<td>10</td>
<td>8</td>
<td>&lt;1</td>
<td>0</td>
<td>&lt;1</td>
<td>7</td>
<td>&lt;1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>9</td>
<td>9</td>
<td>30</td>
<td>0</td>
<td>&lt;1</td>
<td>1</td>
<td>8</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Bone pain</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>6</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>5</td>
<td>3</td>
<td>8</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>5</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Musculo skeletal and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>connective tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>12</td>
<td>11</td>
<td>13</td>
<td>0</td>
<td>&lt;1</td>
<td>1</td>
<td>17</td>
<td>1</td>
<td>1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Asthenia</td>
<td>9</td>
<td>5</td>
<td>9</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>0</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Oedema peripheral</td>
<td>5</td>
<td>7</td>
<td>18</td>
<td>&lt;1</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

1 Also includes preferred term anorexia

Percentages are rounded to integer for presentation in this table. However, percentages with one decimal precision are used to identify terms with a frequency of at least 5% and to classify terms according to frequency categories.
Less Common Clinical Trial Adverse Drug Reactions (< 5%)

Additional Data from Clinical Trials (Studies A2101 and A2303)

The following adverse drug reactions (ADRs) were reported in adult patients in the TASIGNA clinical studies which serve as a basis for the listed indications at the recommended doses at a frequency of less than 5% (common is ≥ 1% to < 10%; uncommon is >0.1% to <1%); (single events are captured as Unknown in frequency- Unknown). For laboratory abnormalities, very common events (≥10%) not included in Table 1 are also reported. These adverse reactions are included based on clinical relevance and ranked in order of decreasing seriousness within each category, obtained from two clinical studies: 1. Newly diagnosed Ph+ CML-CP 60 months’ analysis and 2. Resistant or intolerant Ph+ CML-CP and CML-AP 24 months’ analysis.

Cardiac Disorders:
*Common:* angina pectoris, arrhythmia (including atrioventricular block, cardiac flutter, extrasystoles, atrial fibrillation, tachycardia, bradycardia), cardiac failure, palpitations, electrocardiogram QT prolonged.
*Uncommon:* myocardial infarction, coronary artery disease, cardiac murmur pericardial effusion, deep vein thrombosis, cyanosis
*Unknown frequency:* myocarditis, ventricular dysfunction, pericarditis, ejection fraction decrease, congenital transposition of great vessels in neonate (fatal), ventricular arrhythmia, cardiac valve disorders

Infections and Infestations:
*Common:* folliculitis, upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis).
*Uncommon:* pneumonia, bronchitis, urinary tract infection, herpes virus infection, candidiasis (including oral candidiasis), gastroenteritis
*Unknown frequency:* sepsis, subcutaneous abscess, anal abscess, furuncle, tinea pedis, hepatitis B virus reactivation.

Neoplasms Benign, Malignant and Unspecified:
*Common:* skin papilloma.
*Unknown frequency:* oral papilloma, paraproteinemia.

Blood and Lymphatic System Disorders:
*Common:* leukopenia, eosinophilia, febrile neutropenia, pancytopenia, lymphopenia.
*Unknown frequency:* thrombocytopenia, leukocytosis.

Endocrine Disorders:
*Uncommon:* hyperthyroidism, hypothyroidism.
*Unknown frequency:* hyperparathyroidism secondary, thyroiditis.

Metabolism and Nutrition Disorders:
*Very common:* hypophosphatemia (including blood phosphorus decreased).
*Common:* electrolyte imbalance (including hypomagnesemia, hyperkalemia, hypokalemia, hyponatremia, hypocalcemia, hypercalcemia, hyperphosphatemia), diabetes mellitus.
(uncommonly specified as Types 1 or 2 diabetes mellitus), hyperglycemia, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia.

*Uncommon:* gout, dehydration, increased appetite, new-onset diabetes, dyslipidemia

*Unknown frequency:* hyperuricemia, hypoglycemia.

**Psychiatric Disorders:**

*Common:* depression, insomnia, anxiety.

*Unknown frequency:* disorientation, confusional state, amnesia, dysphoria.

**Nervous System Disorders:**

*Common:* dizziness, peripheral neuropathy, hypoesthesia, paresthesia.

*Uncommon:* intracranial hemorrhage, ischemic stroke, transient ischemic attack, cerebral infarction, migraine, loss of consciousness (including syncope), tremor, disturbance in attention, hyperesthesia.

*Unknown frequency:* cerebrovascular accident, basilar artery stenosis, brain oedema, optic neuritis, lethargy, dysaesthesia, restless legs syndrome.

**Eye Disorders:**

*Common:* eye hemorrhage, periorbital oedema, eye pruritus, conjunctivitis, dry eye (including xerophthalmia).

*Uncommon:* vision impairment, vision blurred, visual acuity reduced, eyelid oedema, photopsia, hyperaemia (scleral, conjunctival, ocular), eye irritation, conjunctival hemorrhage.

*Unknown frequency:* papilloedema, diplopia, photophobia, eye swelling, blepharitis, eye pain, chorioretinopathy, conjunctivitis allergic, ocular surface disease.

**Ear and Labyrinth Disorders:**

*Common:* vertigo.

*Unknown frequency:* hearing impaired, ear pain, tinnitus.

**Immune System Disorders:**

*Unknown frequency:* vasculitis (cerebral, leukocytoclastic), hypersensitivity.

**Vascular Disorders:**

*Common:* hypertension, flushing.

*Uncommon:* hypertensive crisis, peripheral arterial occlusive disease (including femoral artery stenosis), coronary artery stenosis, carotid artery stenosis, arterial stenosis limb, cerebrovascular accident, hematoma, arteriosclerosis.

*Unknown frequency:* shock hemorrhagic, arteriosclerosis obliterans, hypotension, thrombosis, cerebral infarction, cerebral hemorrhage, amnestic disorder, peripheral vascular disorder, intermittent claudication, vasculitis, circulatory collapse, venous stenosis, arterial disorder, femoral artery occlusion, aortic arteriosclerosis, peripheral ischaemia, arterial occlusive disease, arteritis obliterans, extravasation blood, vascular graft occlusion, peripheral artery stenosis.

**Respiratory, Thoracic and Mediastinal Disorders:**

*Common:* dyspnea, dyspnea exertional, epistaxis, cough, dysphonia.

*Uncommon:* pulmonary oedema, pleural effusion, interstitial lung disease, pleuritic pain, pleurisy, pharyngolaryngeal pain, throat irritation.
Unknown frequency: pulmonary hypertension, wheezing, oropharyngeal pain.

**Gastrointestinal Disorders:**
*Common:* acute pancreatitis, abdominal discomfort, abdominal distension, dyspepsia, dysgeusia, flatulence.
*Uncommon:* gastrointestinal hemorrhage, melaena, mouth ulceration, gastroesophageal reflux, stomatitis, oesophageal pain, dry mouth, gastritis, sensitivity of teeth.
*Unknown frequency:* gastrointestinal ulcer perforation, retroperitoneal hemorrhage, hematemesis, gastric ulcer, esophagitis ulcerative, subileus, enterocolitis, hemorrhoids, hiatus hernia, rectal hemorrhage, gingivitis.

**Hepatobiliary Disorders:**
*Very common:* hyperbilirubinemia (including blood bilirubin increased).
*Common:* hepatic function abnormal.
*Uncommon:* hepatic failure, hepatotoxicity, toxic hepatitis, ascites, jaundice.
*Unknown frequency:* cholestasis, hepatic necrosis, hepatic steatosis, hepatomegaly.

**Skin and Subcutaneous Tissue Disorders:**
*Common:* night sweats, eczema, urticaria, hyperhidrosis, contusion, acne, dermatitis, (including allergic, exfoliative and acneform).
*Uncommon:* exfoliative rash, drug eruption, pain of skin, ecchymosis, swelling face.
*Unknown frequency:* psoriasis, erythema multiforme, skin fissures, erythema nodosum, skin ulcer, palmar-plantar erythrodysaesthesia syndrome, petechiae, photosensitivity, blister, dermal cyst, sebaceous hyperplasia, skin atrophy, skin discolouration, skin exfoliation, skin hyperpigmentation, skin hypertrophy, hyperkeratosis.

**Musculoskeletal and Connective Tissue Disorders:**
*Common:* musculoskeletal chest pain, musculoskeletal pain, back pain, neck pain, flank pain, muscular weakness.
*Uncommon:* musculoskeletal stiffness, joint swelling.
*Unknown frequency:* rhabdomyolysis, arthritis.

**Renal and Urinary Disorders:**
*Common:* pollakiuria.
*Uncommon:* dysuria, micturition urgency, nocturia, acute renal failure.
*Unknown frequency:* renal failure, hematuria, urinary incontinence, chromaturia.

**Reproductive System and Breast Disorders:**
*Uncommon:* breast pain, gynecomastia, erectile dysfunction.
*Unknown frequency:* breast induration, menorrhagia, nipple swelling.

**General Disorders and Administration Site Conditions:**
*Common:* pyrexia, chest pain (including non-cardiac chest pain), pain chest discomfort, malaise.
*Uncommon:* face edema, gravitational edema, influenza-like illness, chills, feeling body temperature change (including feeling hot, feeling cold).
*Unknown frequency:* localised oedema.
**Investigations:**

*Very common:* alanine aminotransferase increased, aspartate aminotransferase increased, lipase increased, lipoprotein cholesterol (including low density and high density) increased, total cholesterol increased, blood triglycerides increased.

*Common:* prothrombin time (INR) increased\(^1\), hemoglobin decreased, blood amylase increased, gamma-glutamyltransferase increased, blood creatine phosphokinase increased, blood alkaline phosphatase increased, weight decreased, blood insulin increased, weight increased, globulins decreased.

*Uncommon:* blood lactate dehydrogenase increased, blood urea increased.

*Unknown frequency:* troponin increased, blood potassium decreased, blood bilirubin unconjugated increased, blood insulin decreased, insulin C-peptide decreased, blood parathyroid hormone increased.

\(^1\) Prolongation of prothrombin time (INR) was reported with common frequency in patients receiving TASIGNA, however causal relationship with TASIGNA has not been confirmed.

**Second malignancies in TASIGNA-treated patients:**

There are reports of second cancers (gastric cancer, gastrointestinal stromal tumour, pancreatic carcinoma, pancreatic neuroendocrine tumour, colon cancer, malignant melanoma in situ, ovarian epithelial cancer, skin cancer, and squamous cell carcinoma) in pooled clinical trials of patients treated with TASIGNA.

**Abnormal Hematologic and Clinical Chemistry Findings – Adults**

Clinically relevant or severe abnormalities of routine hematologic or biochemistry laboratory values in adult patients are presented in Table 2.

**Table 2 Grade 3/4 Laboratory Abnormalities**

<table>
<thead>
<tr>
<th></th>
<th>Newly diagnosed Adult Ph+ CML-CP</th>
<th>Resistant or intolerant Adult Ph+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TASIGNA 300 mg twice daily N = 279</td>
<td>TASIGNA 400 mg twice daily N = 277</td>
</tr>
<tr>
<td>Hematologic parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myelosuppression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>12%</td>
<td>11%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>10%</td>
<td>12%</td>
</tr>
<tr>
<td>Anemia</td>
<td>4%</td>
<td>5%</td>
</tr>
<tr>
<td>Biochemistry parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevated creatinine</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Elevated lipase</td>
<td>9%</td>
<td>10%</td>
</tr>
</tbody>
</table>
Elevated SGOT (AST) | 1% | 3% | 1% | 3% | 2%
Elevated SGPT (ALT) | 4% | 9% | 3% | 4% | 4%
Hypophosphatemia | 8% | 10% | 10% | 17% | 15%
Elevated Bilirubin (total) | 4% | 9% | <1% | 7% | 9%
Hyperglycemia | 7% | 7% | <1% | 12% | 6%
Hyperkalemia | 2% | 1% | 1% | 6% | 4%
Hyponatremia | 1% | 1% | <1% | 7% | 7%
Hypokalemia | <1% | 1% | 2% | 2% | 9%
Hypocalcemia | <1% | <1% | <1% | 2% | 5%
Decreased albumin | 0% | 0% | <1% | 4% | 3%
Elevated alkaline phosphatase | 0% | 0% | <1% | <1% | 1%
Elevated cholesterol (total) | 0 | 1% | 0% | ** | **
Elevated triglycerides | 0% | <1% | 0% | ** | **

Percentages with one decimal precision are used and rounded to integer for presentation in this table.
* parameter not collected

Abnormal Electrocardiographic (ECG) Findings - Adults

In the Phase III study (A2303) in adults newly diagnosed with Ph+ CML-CP, no patient had an absolute QTcF exceeding 500 msec while on treatment in any of the treatment groups. QTcF increase from baseline that exceeds 60 msec was observed in 1 patient (0.4%) in the TASIGNA 300 mg twice daily treatment group and 4 (1.4%) in the TASIGNA 400 mg twice daily treatment group (See Table 3). No episodes of Torsades de Pointes were observed.

In the Phase II study (A2101) in adults with imatinib-resistant or -intolerant CML in CP and AP, QTcF exceeding 500 msec was observed in 4 patients (1.2%) of CML-CP patients. QTcF > 60 msec increase from baseline was observed in the combined CML-CP and –AP patient populations (CML-CP 8 (2.5%) and CML-AP 11 (8%) (See Table 4). No episodes of Torsades de Pointes (transient or sustained) were observed (see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS).

Table 3 Number (%) of newly diagnosed Ph+ CML-CP adult patients with notable values in QTcF intervals-Study A2303

<table>
<thead>
<tr>
<th>ECG Parameter</th>
<th>TASIGNA 300 mg twice daily</th>
<th>TASIGNA 400 mg twice daily</th>
<th>GLEEVEC 400 mg once daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 279</td>
<td>N = 277</td>
<td>N = 280</td>
<td></td>
</tr>
<tr>
<td>Increase from baseline &gt; 30 msec</td>
<td>94 (33.7)</td>
<td>91 (32.9)</td>
<td>82 (29.3)</td>
</tr>
<tr>
<td>Increase from baseline &gt; 60 msec</td>
<td>1 (0.4)</td>
<td>4 (1.4)</td>
<td>4 (1.4)</td>
</tr>
</tbody>
</table>
Table 4  Number (%) of imatinib- resistant or -intolerant Ph+ CML-CP and CML-AP adult patients with notable values in QTcF intervals-Studies 2101E2 and 2101E1

<table>
<thead>
<tr>
<th>ECG Parameter</th>
<th>CML-CP (2101E2) N= 321 n (%)</th>
<th>CML-AP (2101E1) N= 137 n (%)</th>
<th>Total N= 458 n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase from baseline &gt; 30 msec</td>
<td>144 (44.9)</td>
<td>65 (47.4)</td>
<td>209 (45.6)</td>
</tr>
<tr>
<td>Increase from baseline &gt; 60 msec</td>
<td>8 (2.5)</td>
<td>11 (8.0)</td>
<td>19 (4.1)</td>
</tr>
<tr>
<td>Absolute value &gt; 450 msec</td>
<td>51(15.9)</td>
<td>24</td>
<td>75(16.4)</td>
</tr>
<tr>
<td>Absolute value &gt; 480 msec</td>
<td>7 (2.2)</td>
<td>4 (2.9)</td>
<td>11(2.4)</td>
</tr>
<tr>
<td>Absolute value &gt; 500 msec</td>
<td>4 (1.2)</td>
<td>0 (0.0)</td>
<td>4 (0.9)</td>
</tr>
</tbody>
</table>

n= number of patients who meet the criterion for at least one post-baseline value.

Treatment discontinuation in Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5)

In eligible patients who discontinued TASIGNA therapy after attaining a sustained MR4.5, musculoskeletal symptoms (e.g. myalgia, pain in extremity, arthralgia, bone pain, spinal pain, or musculoskeletal pain), were reported more frequently than before treatment discontinuation in the first year, as noted in Table 5. The frequency of new musculoskeletal symptoms generally decreased in the second year after treatment discontinuation.

In the newly diagnosed population in whom musculoskeletal symptoms occurred at any time during the TFR phase, for 23/53 patients (43.4%) the event had not resolved by the TFR end date or as of the 96-weeks TFR analysis data cut-off date. In the population previously treated with imatinib in whom musculoskeletal events occurred at any time during the TFR phase, for 32/57 patients (56.1%) the event had not resolved by the TFR end date or by the data cut-off date.

The frequency of musculoskeletal symptoms decreased in patients who entered the TASIGNA treatment re-initiation (NTRI) phase, to 11/88 patients (12.5%) in the newly diagnosed population and to 14/56 patients (25%) in the population previously treated with imatinib. Other adverse reactions observed in the TASIGNA re-treatment phase were similar to those observed during TASIGNA use in patients with newly diagnosed Ph+ CML-CP and resistant or intolerant Ph+ CML-CP and CML-AP.
Table 5 Musculoskeletal symptoms occurring upon treatment discontinuation in the context of treatment-free remission (TFR)

<table>
<thead>
<tr>
<th></th>
<th>Entire TFR period in all TFR patients</th>
<th>By time interval, in subset of patients in TFR greater than 48 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Median follow-up in TFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph+ CML-CP patients</td>
<td>Newly Diagnosed</td>
<td>190</td>
</tr>
<tr>
<td></td>
<td>Previously treated with imatinib</td>
<td>126</td>
</tr>
</tbody>
</table>

Safety of TASIGNA in Pediatric Patients with Newly Diagnosed or Resistant/Intolerant Ph+ CML-CP

The safety of TASIGNA in pediatric patients (from 2 to <18 years of age) with Ph+ CML-CP (N=69) has been investigated in two open-label single arm studies, (Phase II, CAMN107A2203 and Phase I, CAMN107A2120) (see CLINICAL TRIALS). The frequency, type and severity of observed adverse reactions have been generally consistent with those observed in adults. The most common newly occurring or worsening hematological laboratory abnormalities (≥ 30% of patients, all grades) were decreases in total white blood cells (54%), platelet count (44%), absolute neutrophils (41%), absolute lymphocytes (32%), and hemoglobin (30%). The most common (>20%) non-hematologic adverse drug reactions were headache, rash, blood bilirubin increased, alanine aminotransferase increased, pyrexia, nausea, upper respiratory tract infection, aspartate aminotransferase increased and vomiting. Liver-related laboratory abnormalities of hyperbilirubinaemia (Grade 3/4: 13.0%) and transaminase elevation (AST Grade 3/4: 1.4%, ALT Grade 3/4: 8.7%) were reported at a higher frequency than in adult patients. Bilirubin and hepatic transaminase levels should be monitored during treatment (see DOSAGE AND ADMINISTRATION and Monitoring and Laboratory Tests). Increase in QTcF >30 msec from baseline was observed in 17 pediatric patients (25%). Increase in QTcF >450 msec was observed in 4 pediatric patients (6.0%), increase in QTcF > 480 msec was observed in 3 pediatric patients (4.4 %). No patient had an absolute QTcF > 500msec or QTcF increase of > 60 msec from baseline.

Growth Retardation in Pediatric Patients:

In the Phase II pediatric study CAMN107A2203 (n=58), with a median exposure of 33 months to TASIGNA, adverse drug reactions of mild and moderate severity associated with growth and deceleration of growth in regard to the height were reported in 3 patients (5.2%) including growth retardation in 2 adolescent patients and growth hormone deficiency with body height below normal in the remaining patient (10 to 13 years old). Twelve percent (n = 7) of patients had growth deceleration as demonstrated by a decrease of two main height percentile lines (percentile lines:
5 th, 10th, 25th , 50th, 75th, 90th, and 95th) on their growth chart during their treatment with TASIGNA.

No negative effects were observed in relation to the bone age or bone biomarkers and no delayed puberty was observed.

**Post-Market Adverse Reactions**

The following adverse reactions have been derived from post marketing experience with TASIGNA via spontaneous case reports, literature cases, expanded access programs, and clinical studies other than the global registration trials. The criteria for including these adverse reactions is based on the seriousness. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Blood and lymphatic:** splenic infarction

**Cardiovascular:** anaphylaxis, cardiac tamponade (fatal), Torsades de Pointes, tricuspid valve incompetence, aortic valve sclerosis, coeliac artery stenosis, disseminated intravascular coagulation,

**Congenital, familial and genetic:** Encephalocele, omphalocele, transposition of great vessels, venous angioma of brain, cerebellar hypoplasia

**Ear and labyrinth:** deafness

**Endocrine and Metabolism:** fluid overload, tumor lysis syndrome

**Eye:** cataract, blindness, conjunctivitis, ocular hyperaemia, visual impairment, eye haemorrhage, periorbital oedema, retinal haemorrhage, optic nerve infarction, optic ischaemic neuropathy, arteriosclerotic retinopathy, optic neuropathy, retinal artery occlusion, optic neuritis

**General:** gait disturbance

**Hepatobiliary:** hepatorenal syndrome, diverticular perforation, intestinal perforation, gastric ulcer haemorrhage

**Immune:** aphthous stomatitis

**Infections and infestations:** Clostridium difficile colitis, lower respiratory tract infection, pelvic abscess, pneumonia primary atypical, septic shock, swine influenza

**Injury, poisoning and procedural complications:** In-stent arterial restenosis

**Investigations:** blood phosphorus increased, positive Rombergism, urine output decreased

**Neoplasms benign, malignant and unspecified (incl cysts and polyps):** biliary adenoma, biliary neoplasm, lung neoplasm malignant, renal cancer, transitional cell carcinoma, lymphoma, leukemia, myelodysplastic syndrome, skin papilloma, thyroid neoplasm, oesophageal adenocarcinoma, throat cancer, rhabdomyosarcoma, metastases to central nervous system, malignant lung neoplasm, bronchial carcinoma, acute lymphocytic leukemia, acute leukemia, squamous cell carcinoma of skin, malignant melanoma, penis carcinoma, carcinoid tumour of
small bowel, ovarian cancer, basal cell carcinoma, myelofibrosis, colon cancer, gastrointestinal stromal tumour

**Nervous system:** convulsion, hepatic encephalopathy, intracranial pressure increased, spinal cord infarction, paralysis, IIIrd nerve paralysis, IVth nerve paralysis, cerebellar infarction, brain herniation, facial paralysis

**Pregnancy, puerperium and perinatal conditions:** Spontaneous abortions, stillbirth, and foetal death

**Psychiatric:** bipolar disorder, hallucination

**Renal and urinary:** calculus ureteric, tubulointerstitial nephritis, urine flow decreased

**Respiratory:** acute respiratory distress syndrome, acute respiratory failure, bronchospasm, hypoxia, pulmonary embolism, respiratory failure, tachypnoea

**Skin and subcutaneous:** Stevens-Johnson syndrome, skin necrosis, palmar-plantar erythrodysaesthesia syndrome, exfoliative dermatitis, toxic epidermal necrolysis

**Vascular:** venous insufficiency, vertebral artery occlusion, cerebral artery stenosis, carotid artery thrombosis, carotid artery occlusion, cerebral artery occlusion, arterial occlusive disease, necrotising vasculitis, aortic stenosis, peripheral embolism, arterial haemorrhage, embolism venous, venous thrombosis, vascular occlusion, veno-occlusive disease

**DRUG INTERACTIONS**

**Overview**

**Drug-Drug Interactions**

<table>
<thead>
<tr>
<th>Serious Drug and Drug-Food Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• CYP3A4 inhibitors should be avoided as they can increase nilotinib serum concentrations.</td>
</tr>
<tr>
<td>• Concomitant use of drugs that prolong QT interval should be avoided.</td>
</tr>
<tr>
<td>• Co-administration with drugs with a narrow therapeutic index and that are eliminated by certain enzymes.</td>
</tr>
<tr>
<td>• TASIGNA absorption is increased if taken with food. TASIGNA must not be taken with food and should be taken 2 hours after a meal. No food should be consumed at least 1 hour after the drug is taken.</td>
</tr>
</tbody>
</table>
Nilotinib is mainly metabolized in the liver, and is also a substrate for the multi-drug efflux pump, P-glycoprotein (P-gp). Therefore, absorption and subsequent elimination of systemically absorbed nilotinib may be influenced by drugs that affect CYP3A4 and/or P-gp. Interaction studies have not been performed in the pediatric population.

**Drugs That May Increase Nilotinib Serum Concentrations**

The administration of TASIGNA with agents that are strong CYP3A4 inhibitors should be avoided. Should treatment with any of these agents be required, it is recommended that therapy with TASIGNA be interrupted if possible. If transient interruption of treatment with TASIGNA is not possible, close monitoring of the individual for prolongation of the QT interval is indicated (see DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY).

In a Phase I study of nilotinib given in combination with imatinib (a substrate of P-gp and CYP3A4), both drugs had individually an inhibitory effect on CYP3A4 and/or P-gp. When the two drugs were administered concomitantly, the AUC of imatinib was increased by 18% to 39%, and the AUC of nilotinib was increased by 18% to 40%.

The bioavailability of nilotinib in healthy subjects was increased by 3-fold when co-administered with the strong CYP3A4 inhibitor ketoconazole. Concurrent treatment with strong CYP3A4 inhibitors should therefore be avoided (including but not limited to ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, and telithromycin). For additional drugs, also refer to http://www.intermed-rx.ca (see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS regarding QT prolongation). Alternative concomitant medications with no or minimal CYP3A4 inhibition should be considered.

**Drugs That May Decrease Nilotinib Serum Concentrations**

In healthy subjects receiving the CYP3A4 inducer, rifampicin, at 600 mg daily for 12 days, systemic exposure (AUC) to TASIGNA was decreased approximately 80%.

Inducers of CYP3A4 activity could increase the metabolism of nilotinib and thereby decrease plasma concentrations of nilotinib. The concomitant administration of medications that induce CYP3A4 (e.g. phenytoin, rifampin, carbamazepine, phenobarbital, and St. John’s Wort) may reduce exposure to nilotinib to a clinically relevant extent. In patients for whom CYP3A4 inducers are indicated, concomitant use of alternative therapeutic agents with less potential for CYP3A4 enzyme induction potential should be considered. For additional drugs, also refer to http://www.intermed-rx.ca.

Nilotinib has pH-dependent solubility, with lower solubility at higher pH. In 22 healthy subjects receiving multiple doses of esomeprazole at 40 mg once daily for 5 days, gastric pH was markedly increased. Co-administration of a single 400 mg dose of nilotinib and 40 mg esomeprazole was associated with a modest decrease in nilotinib absorption (27% decrease in nilotinib C_{max} and 34% decrease in nilotinib AUC_{0-\infty}). TASIGNA may be used concurrently with esomeprazole or other proton pump inhibitors as needed.

In a study with 52 healthy subjects, no significant change in nilotinib pharmacokinetics was observed when a single 400 mg dose of TASIGNA was administered 10 hours after and 2 hours
before famotidine. Therefore, when the concurrent use of an H2 blocker is necessary, it may be administered approximately 10 hours before and approximately 2 hours after the dose of TASIGNA.

In the same study as above, administration of a “non-absorbable” antacid (aluminum hydroxide/magnesium hydroxide/simethicone) 2 hours before or after a single 400 mg dose of TASIGNA also did not alter nilotinib pharmacokinetics. Therefore, if necessary, a “non-absorbable” antacid may be administered approximately 2 hours before or approximately 2 hours after the dose of TASIGNA.

**Drugs That May Have Their Systemic Concentration Altered By Nilotinib**

*In vitro* nilotinib is identified as a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, and CYP2D6 and UGT1A1, with Ki value being lowest for CYP2C9 (Ki=0.13 μM) (Substrates of UGT1A1: including but not limited to buprenorphine, phenytoin). A single-dose drug-drug interaction study with 25 mg warfarin, a sensitive CYP2C9 substrate, and 800 mg nilotinib was conducted in 24 healthy subjects. Nilotinib at clinically relevant concentrations was not found to alter the pharmacokinetics or pharmacodynamics of warfarin, a sensitive CYP2C9 substrate. TASIGNA can be used concurrently with warfarin without increasing the anticoagulant effect. Due to lack of steady-state data, control of warfarin pharmacodynamic markers (INR or PT) following initiation of nilotinib therapy (at least during the first 2 weeks) is recommended.

In 19 CML patients, nilotinib administered at 400 mg twice daily for 12 days increased the systemic exposure (AUC) of a single 2 mg oral dose of midazolam (a substrate of CYP3A4) 2.6-fold. Nilotinib is a moderate CYP3A4 inhibitor. As a result, the systemic exposure of other drugs primarily metabolized by CYP3A4 (e.g. certain hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors or statins) may be increased when co-administered with nilotinib. Appropriate monitoring and dose adjustment may be necessary for drugs that are CYP3A4 substrates and have a narrow therapeutic index (including but not limited to opioids (alfentanil, fentanyl), immunosuppressants (cyclosporine, sirolimus and tacrolimus), vasoconstrictors (dihydroergotamine and ergotamine), and levothyroxine) when co-administered with nilotinib (see Monitoring and Laboratory Tests). For additional drugs, also refer to [http://www.intermed-rx.ca](http://www.intermed-rx.ca).

Nilotinib is a P-gp inhibitor *in vitro*. Therefore, concentration of drugs which are substrates of P-gp (including but not limited to verapamil, digoxin, morphine, phenytoin, cefazolin, cyclosporine A, ondansetron) may be increased. Alternative concomitant medications which are not P-gp substrates should be considered.

**Anti-arrhythmic Medicines and Other Drugs That May Prolong the QT Interval**

Concomitant use of TASIGNA with *anti-arrhythmic medicines* (including, but not limited to amiodarone, disopyramide, procainamide, quinidine and sotalol) and other drugs that may prolong the QT interval (including, but not limited to chloroquine, halofantrine, clarithromycin, and other macrolides, haloperidol, methadone, moxifloxacin, bepridil and pimozide) should be avoided. (see WARNINGS AND PRECAUTIONS).

Concomitant use of *anti-emetic medicines* (including but not limited to metoclopramide, prochlorperazine, ondansetron and dolasetron) should be avoided.
The concomitant use of TASIGNA with another QT/QTc-prolonging drug is discouraged. Drugs that have been associated with QT/QTc interval prolongation and/or Torsades de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QT/QTc prolongation and/or Torsades de pointes:

• Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide);
• Class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide);
• Class 1C antiarrhythmics (e.g., flecainide, propafenone);
• antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone);
• antidepressants (e.g., fluoxetine, citalopram, venlafaxine, tricyclic/tetracyclic antidepressants e.g., amitriptyline, imipramine, maprotiline);
• opioids (e.g., methadone);
• macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, telithromycin, tacrolimus);
• quinolone antibiotics (e.g., moxifloxacin, levofloxacin, ciprofloxacin);
• pentamidine;
• antimalarials (e.g., quinine, chloroquine);
• azole antifungals (e.g., ketoconazole, fluconazole, voriconazole);
• domperidone;
• 5-hydroxytryptamine (5-HT)3 receptor antagonists (e.g., dolasetron, ondansetron);
• tyrosine kinase inhibitors (e.g., sunitinib, lapatinib);
• histone deacetylase inhibitors (e.g., vorinostat);
• beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol).

The use of TASIGNA is discouraged with drugs that can disrupt electrolyte levels, including, but not limited to, the following:

• loop, thiazide, and related diuretics;
• laxatives and enemas;
• amphotericin B;
• high dose corticosteroids.

The above lists of potentially interacting drugs are not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QT/QTc interval, inhibit metabolizing enzymes and/or transports, or cause electrolyte disturbances, as well as for older drugs for which these effects have recently been established.

Drug-Food Interactions

Food-effect

The bioavailability of nilotinib is increased by food. TASIGNA must not be taken in conjunction with food (see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS
and ACTION AND CLINICAL PHARMACOLOGY) and should be taken 2 hours after a meal. No food should be consumed for at least one hour after the dose is taken.

For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of applesauce and should be taken immediately. Not more than one teaspoon of applesauce should be used. Yogurt was shown to result in a significant increase in bioavailability and therefore must be avoided and no food other than applesauce must be used (see DOSAGE AND ADMINISTRATION).

Products and juices containing grapefruit, star fruit, pomegranate, Seville oranges and other similar fruits that are known to inhibit CYP3A4 should be avoided at any time.

The absorption of TASIGNA is increased if it is taken with food, resulting in higher serum concentration (see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS and ACTION AND CLINICAL PHARMACOLOGY).

Drug-Herb Interactions
St. John’s Wort is a potent CYP3A4 inducer. Co-administration with TASIGNA may lead to increased TASIGNA metabolism, therefore decreased TASIGNA serum concentrations (see Drug-Drug Interactions).

Drug-Laboratory Interactions
Interactions with laboratory tests have not been established.

Drug-Lifestyle Interactions
Please refer to sections on DOSAGE AND ADMINISTRATION and INTERACTIONS.

Effects on ability to drive and use machines
No studies on the effects of nilotinib on the ability to drive and operate machines have been performed. Patients experiencing dizziness, visual impairment or other undesirable effects with a potential impact on the ability to safely drive or use machines should refrain from these activities as long as these undesirable effects persist (see ADVERSE REACTIONS).

Alcohol

No studies have been performed on the potential interaction between nilotinib and alcohol consumption. There is a single report of reduced efficacy of nilotinib in a patient concomitantly consuming alcohol.

Food

The bioavailability of nilotinib is increased by food. TASIGNA must not be taken in conjunction with food and should be taken 2 hours after a meal. No food should be consumed for at least one hour after the dose is taken. Grapefruit juice and other foods that are known to inhibit CYP3A4 should be avoided at any time.
DOSAGE AND ADMINISTRATION

Dosing Considerations

Pediatric patients (2 to < 18 years)
The safety and efficacy of TASIGNA in pediatric patients with Ph+ CML-CP from 2 to less than 18 years of age has been established (see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY, and CLINICAL TRIALS). There is no experience in pediatric patients below 2 years of age or in pediatric patients with Ph+ CML-AP or blast crisis (BC).

Patients with renal impairment
Clinical studies have not been performed in patients with impaired renal function. Clinical studies have excluded patients with serum creatinine concentration >1.5 times the upper limit of the normal range.
TASIGNA and its metabolites are not renally excreted (See Pharmacokinetics).

Patients with hepatic impairment
Hepatic impairment has an effect on the pharmacokinetics of nilotinib in adults. Dose adjustment is not considered necessary in hepatically impaired patients. Patients with hepatic impairment should be treated with caution and careful clinical monitoring, including close monitoring of the QTc interval (see WARNINGS AND PRECAUTIONS).

Cardiac disorders
In clinical studies, newly diagnosed Ph+ CML-CP and imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients with any of the following uncontrolled or significant cardiac disease were excluded: recent myocardial infarction, CHF, unstable angina, or clinically significant bradycardia. Imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients with complete left bundle branch block and/or right bundle branch block, with left anterior hemiblock, or with bifascicular block were excluded from the study. Newly diagnosed Ph+ CML-CP patients with complete left bundle branch block were also excluded. ECG and cardiac enzyme monitoring were conducted in patients throughout the studies. Caution should be exercised in patients with relevant cardiac disorders (see WARNINGS AND PRECAUTIONS).

Patients at risk of tumour lysis syndrome
Due to possible occurrence of Tumour Lysis Syndrome (TLS) it is recommended to measure serum levels of creatinine, uric acid, phosphate, potassium, corrected calcium and LDH prior to the initiation of treatment with TASIGNA in order to assess the risk or presence of TLS and to monitor these parameters during the initial period of treatment with TASIGNA until a significant reduction of tumour cell burden has been achieved. Prophylaxis of TLS such as hydration and treatment of high uric acid levels in patients at risk and treatment of abnormalities subsequent to established TLS is required.
Method of administration

TASIGNA should be taken twice daily, at approximately 12 hour intervals and must not be taken with food. The capsules should be swallowed whole with water. No food should be consumed for at least 2 hours before the dose is taken and no additional food should be consumed for at least one hour after the dose is taken (see WARNINGS AND PRECAUTIONS, and DRUG INTERACTIONS).

For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of applesauce and should be taken immediately. Not more than one teaspoon of applesauce should be used. Yogurt was shown to result in a significant increase in bioavailability and therefore must be avoided and no food other than applesauce must be used (see ACTION AND CLINICAL PHARMACOLOGY).

Recommended Dose and Dosage Adjustment

TASIGNA is available in three dosage strengths (50 mg, 150 mg and 200 mg).

Treatment with TASIGNA (nilotinib capsules) should be initiated by a physician experienced in the treatment of patients with CML.

In the adult clinical studies, TASIGNA was allowed to be given in combination with hematopoietic growth factors such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) if clinically indicated. In the adult studies, TASIGNA was also allowed to be given with hydroxyurea (permitted during the first 28 days of treatment, up to 5 g/day for a maximum of 7 days) or anagrelide (permitted during the first 28 days of treatment) if clinically indicated.

Recommended Dose:

Adult patients with newly diagnosed Ph+ CML-CP

The recommended dose of TASIGNA is 300 mg (2x 150 mg capsules) orally twice daily (see CLINICAL TRIALS). Treatment should continue as long as the patient continues to benefit.

Ph+ CML-CP and CML-AP adult patients who are resistant to or intolerant to at least one prior therapy including imatinib:

The recommended dose of TASIGNA is 400 mg (2x 200 mg capsules) orally twice daily (see CLINICAL TRIALS). Treatment should continue as long as the patient does not show evidence of progression or unacceptable toxicity.

A baseline ECG is recommended prior to initiating therapy with TASIGNA and should be repeated after 7 days and as clinically indicated. Hypokalemia or hypomagnesemia must be corrected prior to TASIGNA administration and potassium and magnesium blood levels should be monitored periodically during therapy, particularly in patients at risk for these electrolyte abnormalities (see WARNINGS AND PRECAUTIONS).

Pediatric patients with newly diagnosed Ph+ CML-CP or resistant or intolerant Ph+ CML-CP

Dosing in pediatric patients is individualized and is based on body surface area (mg/m²). The recommended dose of TASIGNA is 230 mg/m² twice daily, rounded to the nearest 50 mg dose.
This dose in pediatric patients had comparable pharmacokinetic exposure as the 400 mg twice daily dose in adults. Different strengths of TASIGNA hard capsules can be combined to attain the desired dose. Treatment should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs. There is no experience with treatment of pediatric patients below 2 years of age.

Table 6 Pediatric dosing of Tasigna (230 mg/m² twice daily, maximum single dose of 400 mg)

<table>
<thead>
<tr>
<th>Body Surface Area (BSA)</th>
<th>Total Daily Dose</th>
<th>Taken as</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 0.32 m²</td>
<td>100 mg</td>
<td>one 50 mg capsule twice a day</td>
</tr>
<tr>
<td>0.33 – 0.54 m²</td>
<td>200 mg</td>
<td>two 50 mg capsules twice a day</td>
</tr>
<tr>
<td>0.55 – 0.76 m²</td>
<td>300 mg</td>
<td>one 150 mg capsule twice a day</td>
</tr>
<tr>
<td>0.77 – 0.97 m²</td>
<td>400 mg</td>
<td>one 200 mg capsule twice a day</td>
</tr>
<tr>
<td>0.98 – 1.19 m²</td>
<td>500 mg</td>
<td>one 50 mg and one 200 mg capsule twice a day</td>
</tr>
<tr>
<td>1.20 – 1.41 m²</td>
<td>600 mg</td>
<td>two 150 mg capsules twice a day</td>
</tr>
<tr>
<td>1.42 – 1.63 m²</td>
<td>700 mg</td>
<td>one 200 mg and one 150 mg capsule twice a day</td>
</tr>
<tr>
<td>≥1.64 m²</td>
<td>800 mg</td>
<td>two 200 mg capsules twice a day</td>
</tr>
</tbody>
</table>

Dose Adjustments or Modifications:
Delay of treatment with TASIGNA in case of established TLS must be weighed in the individual patient against the risk of delayed control of tumour cell proliferation.

TASIGNA may need to be temporarily withheld and/or dose reduced for hematological toxicities (neutropenia, thrombocytopenia) that are not related to underlying leukemia (see Table 7 below).

Table 7 Dose Adjustments for Adult and Pediatric Patients with Neutropenia and Thrombocytopenia

| Adult patients with: - Newly diagnosed Ph+ CML in chronic phase at 300 mg twice daily | ANC# < 1.0 x 10⁹/L and/or platelet counts <50 x 10⁹/L | 1. Stop TASIGNA, and monitor blood counts. 2. Resume within 2 weeks at prior dose if ANC > 1.0x 10⁹/L and/or platelets >50 x 10⁹/L. |
- Resistant or intolerant Ph+ CML in chronic phase or accelerated phase CML at 400 mg twice daily

3. If blood counts remain low for greater than 2 weeks, a dose reduction to 400 mg once daily may be required.

Pediatric patients with:
- Newly diagnosed CML in chronic phase at 230 mg/m² twice daily
- Resistant or intolerant CML in chronic phase at 230 mg/m² twice daily

ANC\(^n\) <1 × 10\(^9\)/L and/or platelet counts <50 × 10\(^9\)/L

1. Stop TASIGNA and monitor blood counts.
2. Resume within 2 weeks at prior dose if ANC >1.5 × 10\(^9\)/L and/or platelets >75 × 10\(^9\)/L.
3. If blood counts remain low for greater than 2 weeks, a dose reduction to 230 mg/m² once daily may be required.
4. If event occurs after dose reduction, consider discontinuing treatment.

\(^n\)ANC= absolute neutrophil count

TASIGNA may need to be temporarily withheld and/or dose reduced for patients who experience QTc interval prolongation (see Table 8 below).

**Table 8 Dose Adjustments for Adult and Pediatric Patients with QT prolongation**

<table>
<thead>
<tr>
<th>ECGs with a QTc &gt; 480 msec</th>
<th>1. Withhold TASIGNA, and perform an analysis of serum potassium and magnesium, and if below lower limit of normal, correct with supplements to within normal limits. Concomitant medication usage must be reviewed.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Resume TASIGNA within 2 weeks at prior dose if QTcF returns to &lt; 450 msec and to within 20 msec of baseline.</td>
</tr>
<tr>
<td></td>
<td>3. If QTcF is between 450 msec and 480 msec after 2 weeks reduce the dose to 400 mg once daily in adults and 230mg/m² once daily in pediatric patients.</td>
</tr>
<tr>
<td></td>
<td>4. If, following dose-reduction to 400 mg once daily in adults and 230mg/m² once daily in pediatric patients, QTcF returns to &gt;480 msec, TASIGNA should be discontinued.</td>
</tr>
<tr>
<td></td>
<td>5. An ECG should be repeated approximately 7 days after any dose adjustment.</td>
</tr>
</tbody>
</table>
See Table 9 below for dose adjustments for elevations of lipase, amylase, bilirubin, and/or hepatic transaminases (see ADVERSE REACTIONS).

**Table 9      Dose Adjustments for Adult and Pediatric Patients with Selected Non-hematologic Laboratory Abnormalities**

<table>
<thead>
<tr>
<th>Elevated serum lipase or amylase ≥ Grade 3</th>
<th>Adult Patients:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Withhold TASIGNA, and monitor serum lipase or amylase</td>
</tr>
<tr>
<td></td>
<td>2. Resume treatment at 400 mg once daily if serum lipase or amylase return to ≤ Grade 1</td>
</tr>
<tr>
<td></td>
<td><strong>Pediatric Patients:</strong></td>
</tr>
<tr>
<td></td>
<td>1. Tasigna must be interrupted until the event returns to less than or equal to Grade 1.</td>
</tr>
<tr>
<td></td>
<td>2. Resume treatment at 230mg/m² once daily if prior dose was 230mg/m² twice daily; if prior dose was 230 mg/m² once daily, treatment should be discontinued.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Elevated Total bilirubin ≥ Grade 3 in adult patients and greater than or equal to Grade 2 in pediatric patients</th>
<th>Adult Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Withhold TASIGNA, and monitor total bilirubin</td>
</tr>
<tr>
<td></td>
<td>2. Resume treatment at 400 mg once daily if total bilirubin return to ≤ Grade 1</td>
</tr>
<tr>
<td></td>
<td>3. Total bilirubin levels should be tested frequently or as clinically indicated</td>
</tr>
<tr>
<td></td>
<td><strong>Pediatric Patients:</strong></td>
</tr>
<tr>
<td></td>
<td>1. Tasigna must be interrupted until the event returns to less than or equal to Grade 1.</td>
</tr>
<tr>
<td></td>
<td>2. Resume treatment at 230mg/m² once daily if prior dose was 230mg/m² twice daily; if prior dose was 230mg/m² once daily, and recovery to less than or equal to Grade 1 takes longer than 28 days, treatment should be discontinued.</td>
</tr>
</tbody>
</table>
Elevated hepatic transaminases ≥ Grade 3

Adult Patients:
1. Withhold TASIGNA, and monitor hepatic transaminases
2. Resume treatment at 400 mg once daily if hepatic transaminases return to ≤ Grade 1
3. Hepatic transaminases levels should be tested frequently or as clinically indicated

Pediatric Patients:
1. Tasigna must be interrupted until the event returns to less than or equal to Grade 1.
2. Resume treatment at 230mg/m² once daily if prior dose was 230mg/m² twice daily; if prior dose was 230mg/m² once daily, and recovery to less than or equal to Grade 1 takes longer than 28 days, treatment should be discontinued.

¹ Serum lipase levels should be tested frequently or as clinically indicated

Serum lipase elevations were observed in adult patients. Few of these elevations were associated with clinical symptoms such as abdominal pain or a diagnosis of pancreatitis. There were 5 cases (1.1%) of pancreatitis reported in imatinib-resistant or-intolerant Ph+ CML-CP and CML-AP patients (N= 458). In adult newly diagnosed Ph+ CML-CP 5 (1.8%) and 8 (2.9%) cases of pancreatitis were reported in patients receiving TASIGNA 300 mg twice daily (N=279) and 400 mg twice daily (N=277), respectively. In case lipase elevations are accompanied by abdominal symptoms, doses should be interrupted and appropriate diagnostics should be considered in order to exclude pancreatitis (see WARNINGS AND PRECAUTIONS).

If clinically significant moderate or severe non-hematologic toxicity develops (including medically severe fluid retention), see Table 10 for dose adjustments (See ADVERSE REACTIONS section).
<table>
<thead>
<tr>
<th>Other clinically moderate or severe non-hematologic toxicity (including fluid retention)</th>
<th>Adult patients:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Withhold Tasigna until toxicity has resolved.</td>
<td></td>
</tr>
<tr>
<td>2. Resume treatment at 400 mg once daily if previous dose was 300 mg twice daily in adult patients newly diagnosed with CML-CP or 400 mg twice daily in adult patients with resistant or intolerant CML-CP and CML-AP.</td>
<td></td>
</tr>
<tr>
<td>3. If the prior dose was 400 mg once daily in adult patients, treatment should be discontinued.</td>
<td></td>
</tr>
<tr>
<td>4. If clinically appropriate, re-escalation of the dose to 300 mg (newly diagnosed Ph+ CML-CP) or 400 mg (resistant or intolerant Ph+ CML-CP and CML-AP) twice daily should be considered.</td>
<td></td>
</tr>
<tr>
<td>Pediatric patients:</td>
<td></td>
</tr>
<tr>
<td>1. Tasigna must be interrupted until toxicity has resolved.</td>
<td></td>
</tr>
<tr>
<td>2. Resume treatment at 230mg/m² once daily if previous dose was 230mg/m² twice daily; if prior dose was 230mg/m² once daily, treatment should be discontinued.</td>
<td></td>
</tr>
<tr>
<td>3. If clinically appropriate, re-escalation of the dose to 230mg/m² twice daily should be considered.</td>
<td></td>
</tr>
</tbody>
</table>

**Discontinuation of treatment after a sustained molecular response (MR4.5) on TASIGNA:**

*Eligibility for Discontinuation of Treatment*

Adult Ph+ CML-CP patients with typical BCR-ABL transcripts who have been taking TASIGNA for a minimum of 3 years and have achieved a sustained molecular response (MR4.5, corresponding to $BCR-ABL/ABL \leq 0.0032\%$ IS) may be eligible for treatment discontinuation (see CLINICAL TRIALS). Discontinuation of TASIGNA treatment in pediatric patients to attempt treatment free remission has not been assessed.

Adult patients with typical $BCR-ABL$ transcripts (i.e., 13a2/b2a2 or e14a2/b3a2) who achieve the sustained MR4.5 criteria are eligible for discontinuation of TASIGNA treatment. Patients must continue to be monitored for possible loss of molecular remission after treatment discontinuation using a quantitative diagnostic test validated with a sensitivity of at least MR4.5 ($BCR-ABL/ABL \leq 0.0032\%$ IS).

Discontinuation of treatment may be considered in adult patients with newly diagnosed Ph+ CML-CP who have:

- been treated with TASIGNA for at least 3 years
- maintained a molecular response of at least MR4.0 (corresponding to $BCR-ABL/ABL \leq 0.01\%$ IS) for at least one year prior to discontinuation of therapy
• achieved an MR4.5 for the last assessment taken immediately prior to discontinuation of therapy

• been confirmed to express the typical $BCR-ABL$ transcripts (e13a2/b2a2 or e14a2/b3a2)

• no history of accelerated phase or blast crisis

• no history of prior attempts of treatment-free remission discontinuation that resulted in relapse.

Discontinuation of treatment may be considered in patients with Ph$^+$ CML-CP that are resistant or intolerant to prior treatment that included imatinib who have achieved a sustained molecular response (MR4.5) on TASIGNA who have:

• been treated with TASIGNA for a minimum of 3 years

• been treated with imatinib only prior to treatment with TASIGNA

• achieved a molecular response of MR4.5 (corresponding to $BCR-ABL/ABL \leq 0.0032\%$ IS)

• sustained MR4.5 for a minimum of one year immediately prior to discontinuation of therapy

• been confirmed to express the typical $BCR-ABL$ transcripts (e13a2/b2a2 or e14a2/b3a2)

• no history of accelerated phase or blast crisis

• no history of prior attempts of treatment-free remission discontinuation that resulted in relapse.

Monitor $BCR-ABL$ transcript levels and complete blood count with differential in patients who have discontinued TASIGNA therapy monthly for one year, then every 6 weeks for the second year, and every 12 weeks thereafter.

Upon loss of MR4.0 (corresponding to $BCR-ABL/ABL \leq 0.01\%$ IS) during the treatment-free phase, monitor $BCR-ABL$ transcript levels every 2 weeks until $BCR-ABL$ levels remain lower than major molecular response (MMR, corresponding to MR3.0 or $BCR-ABL/ABL \leq 0.1\%$ IS) for 4 consecutive measurements. The patient can then proceed to the original monitoring schedule.

Re-initiation of treatment in patients who lose molecular response after discontinuation of therapy with TASIGNA:

• Newly diagnosed patients who lose MMR must reinitiate treatment within 4 weeks at the dose level prior to discontinuation of therapy. Patients who reinitiate TASIGNA therapy should have their $BCR-ABL$ transcript levels monitored monthly until MMR is re-established and every 12 weeks thereafter.

• Ph$^+$ CML-CP patients resistant or intolerant to prior treatment that included imatinib with confirmed loss of MR4.0 (2 consecutive measures separated by at least 4 weeks showing loss of MR4.0) or loss of MMR must reinitiate treatment within 4 weeks at the dose level prior to
discontinuation of therapy. Patients who reinitiate TASIGNA therapy should have their BCR-ABL transcript levels monitored monthly until previous MMR or MR4.0 is re-established and every 12 weeks thereafter.

**Missed Dose**

If a dose is missed, the patient should not take an additional dose, but take the next scheduled usual prescribed dose.

**OVERDOSAGE**

Isolated reports of intentional overdose with nilotinib were reported, where an unspecified number of TASIGNA capsules were ingested in combination with alcohol and other drugs. Events included neutropenia, vomiting and drowsiness. No ECG changes or hepatotoxicity were reported. Outcomes were reported as recovered. One case of accidental overdose in a patient who took a second dose of TASIGNA 400mg shortly after having ingested a first dose of 400 mg. Approximately 8 hours after ingestion, the patient reported feeling weak, abdominal pain, tachycardia and epistaxis.

In the event of overdose, the patient should be observed and appropriate supportive treatment given.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

Pharmacotherapeutic group: Antineoplastic agents - Protein-tyrosine kinase inhibitor ATC code: L01XE08.

TASIGNA is a potent and selective inhibitor of the ABL tyrosine kinase activity of the BCR-ABL oncoprotein both in cell lines and in primary Philadelphia-chromosome positive leukemia cells. The drug binds strongly within the ATP-binding site in such a manner that it is a potent inhibitor of wild-type BCR-ABL and maintains activity against 32/33 imatinib-resistant mutant forms of BCR-ABL with the T315I mutant being the exception. As a consequence of this biochemical activity, nilotinib selectively inhibits the proliferation and induces apoptosis in cell lines and in primary Philadelphia-chromosome positive leukemia cells from CML patients. In murine models of CML, as a single agent nilotinib reduces tumour burden and prolongs survival following oral administration.

TASIGNA has also little or no effect against the majority of other protein kinases examined, except for PDGFRα, PDGFRβ, Kit CSF-1R, DDR-1 and DDR-2 and Ephrin receptor kinases which it inhibits at concentrations within the range achieved following oral administration at therapeutic doses recommended for the treatment of CML (see Table 11).
Table 11  Kinase Profile of nilotinib (Phosphorylation IC_{50} nM)

<table>
<thead>
<tr>
<th>Kinase</th>
<th>BCR-ABL</th>
<th>PDGFR</th>
<th>KIT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>20</td>
<td>69</td>
<td>210</td>
</tr>
</tbody>
</table>

**Pharmacodynamics**
A dose response in the Phase IA component of Study 2101 was explored using the following initial dose cohorts based on daily exposure to nilotinib. The twice daily doses were associated with higher exposures as compared to the once daily doses (See Table 12 below).

Table 12  Dose and corresponding exposure in all adult patients or CML-AP patients

<table>
<thead>
<tr>
<th>Group</th>
<th>Initial dose (mg)</th>
<th>Regimen</th>
<th>Exposure</th>
<th>Steady-state (day 15) AUC_{0-24h} (ng·h/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>All patients a)</td>
<td>CML-AP patients b)</td>
</tr>
<tr>
<td>1</td>
<td>50-200</td>
<td>once daily</td>
<td>Low</td>
<td>6880 (4750)</td>
</tr>
<tr>
<td>2</td>
<td>400-1200</td>
<td>once daily</td>
<td>Middle</td>
<td>26000 (13800)</td>
</tr>
<tr>
<td>3</td>
<td>400</td>
<td>twice daily</td>
<td>High</td>
<td>36000 (11800)</td>
</tr>
<tr>
<td>4</td>
<td>600</td>
<td>twice daily</td>
<td>High</td>
<td>32800 (13800)</td>
</tr>
</tbody>
</table>

a) Mean (SD) of dose group  
b) Median (range) of dose group

**Pharmacokinetics - Adults**

Table 13  Summary of nilotinib’s pharmacokinetic parameters in serum plasma after a single 400 mg oral dose in healthy adult male volunteers (n=4)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>t_{max}</td>
<td>3.5 hours</td>
</tr>
<tr>
<td>C_{max}</td>
<td>599 ng/mL</td>
</tr>
<tr>
<td>t_{1/2}</td>
<td>17 hours</td>
</tr>
<tr>
<td>AUC_{0-24}</td>
<td>20700 ng·h/mL</td>
</tr>
<tr>
<td>Clearance</td>
<td>29.1 L/hour</td>
</tr>
<tr>
<td>V_{d}</td>
<td>579 L</td>
</tr>
</tbody>
</table>

1  values are median for t_{max} and mean for all others

**Absorption:**
Peak concentrations of nilotinib are reached 3 hours after oral administration. Nilotinib absorption following oral administration was approximately 30%. The absolute bioavailability of nilotinib has not been determined.

In healthy volunteers, C_{max} and area under the serum concentration-time curve (AUC) of nilotinib are increased by 112% and 82%, respectively compared to fasting conditions when TASIGNA is given with food. Administration of TASIGNA 30 minutes or 2 hours after food increased bioavailability of nilotinib by 29% or 15%, respectively (see DOSAGE AND
ADMINISTRATION, and DRUG INTERACTIONS). Nilotinib absorption (relative bioavailability) was reduced by approximately 48% and 22% in patients with total gastrectomy and partial gastrectomy, respectively. Mean steady state trough concentration of nilotinib in patients with total gastrectomy was 599 ng/mL vs. 1035 ng/mL in patients without prior GI resection.

In healthy subjects, single dose administration of 400 mg of nilotinib, using 2 capsules of 200 mg whereby the content of each capsule was dispersed in one teaspoon of applesauce, was shown to be bioequivalent with a single dose administration of 2 intact capsules of 200 mg.

Distribution:
Blood-to-plasma ratio of nilotinib is 0.68. Plasma protein binding is approximately 98% on the basis of in vitro experiments.

Metabolism:
Main metabolic pathways identified in healthy subjects are oxidation and hydroxylation. Nilotinib is the main circulating component in the serum. None of the metabolites contribute significantly to the pharmacological activity of nilotinib.

Excretion:
After a single dose of radiolabelled nilotinib in healthy subjects, greater than 90% of the dose was eliminated within 7 days mainly in feces. Parent drug accounted for 69% of the dose. The apparent elimination half-life estimated from the multiple dose PK with daily dosing was approximately 17 hours. Inter-patient variability in nilotinib PK was moderate to high.

Linearity / non-linearity
Steady-state nilotinib exposure was dose-dependent with less than dose-proportional increases in systemic exposure at dose levels higher than 400 mg given as once daily dosing. Daily systemic exposure to nilotinib of 400 mg twice-daily dosing at steady state was 35% higher than with 800 mg once-daily dosing. Systemic exposure (AUC) of nilotinib at steady state at a dose level of 400 mg twice daily was approximately 13.4% higher than with 300 mg twice daily, based on a full pharmacokinetic profile comparison. The average nilotinib trough and peak concentrations over 12 months, obtained from 275 patients in the nilotinib 300 mg twice daily and 267 patients in the nilotinib 400 mg twice daily, were approximately 15.7% and 14.8% higher following 400 mg twice daily dosing compared to 300 mg twice daily. There was no relevant increase in exposure to nilotinib when the dose was increased from 400 mg twice-daily to 600 mg twice-daily.

Steady-state conditions were essentially achieved by day 8. An increase in serum exposure to nilotinib between the first dose and steady state was approximately 2-fold for daily dosing and 3.8-fold for twice-daily dosing.

Special Populations and Conditions:
Pediatric pharmacokinetics: Following administration of nilotinib in pediatric patients at 230 mg/m² twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg), steady-state exposure and clearance of nilotinib were found to be similar (within 2-fold) to adult patients treated with 400 mg twice daily. Overall steady-state exposure of nilotinib as measured
by Ctrough are similar between the two age groups 2 to < 12 years and 12 to 18 years (mean Ctrough ranged from 1540 ng/mL to 1910 ng/mL for the younger group (2 to <12 years) compared to a range of 1200 ng/mL to 1640 ng/mL for the older group (12 to 18 years).

Furthermore, individual predictions from the PopPK study were consistent with observed data, showing similarity across age groups. Medians of individual predictions of BSA-normalized clearances (L/h/m2) in the 2 to < 12 y, 12 to < 18 y, and ≥18 y age groups were 13.8, 13.1, and 13.0 L/h/m2, respectively. Medians of individual predictions of AUCss in the 2 to < 12 y, 12 to < 18 y, and ≥18 y age groups were 16600, 17300, 15300 h·ng/mL, respectively.

Effect of age or gender on PK: Age, body weight, or ethnic origin do not significantly affect the pharmacokinetics of nilotinib in adult patients, whereas there is an effect of gender, with exposure to nilotinib in female patients being approximately 20% greater than in male patients. The PK exposure in pediatric trials was based prospectively on dosing by body surface area (BSA) with a dose of 230 mg/m² twice daily rounded to the nearest multiple of 50 mg not to exceed 400 mg. The effects of body surface area played the major role for accounting for differences in pharmacokinetics between pediatrics (ages 2 to <18 y) and adults, and thus justifying a mg/m² dosing in pediatrics. This dose in children had comparable PK exposure as the 400 mg twice daily dose in adults.

Pharmacogenomics: TASIGNA can lead to elevated bilirubin levels. A pharmacogenetic analysis of 101 imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients was conducted to evaluate the polymorphisms of UGT1A1 and its potential association with hyperbilirubinemia during TASIGNA treatment. In this study, the (TA)7/(TA)7 genotype was associated with a statistically significant increase in the risk of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes. The largest increases in bilirubin were observed in patients with the (TA)7/(TA)7 genotype. Caution is recommended in patients with (TA)7/(TA)7 genotype. (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Patients with hepatic impairment: Hepatic impairment has an effect on the pharmacokinetics of TASIGNA. Single dose administration of TASIGNA 200 mg resulted in increases in AUC of 35%, 35% and 56% in subjects with mild, moderate and severe hepatic impairment, respectively, compared to a control group of subjects with normal hepatic function. The steady-state Cmax of TASIGNA will likely to be increased by up to approximately 29% in subjects with hepatic impairment (see DOSAGE AND ADMINISTRATION).

STORAGE AND STABILITY

Store at room temperature (15-30°C).

Store in the original package.

TASIGNA must be kept out of reach and sight of children.

SPECIAL HANDLING INSTRUCTIONS
No special requirements.

DOSAGE FORMS, COMPOSITION AND PACKAGING

*TASIGNA (nilotinib capsules) 50 mg Hard Capsules:*
Each capsule contains 50 mg nilotinib base (as hydrochloride monohydrate).
White to yellowish powder in hard gelatin capsule with red opaque cap and light yellow opaque body, size 4 with black radial imprint “NVR/ABL” on cap.

*Non-medicinal Ingredients:*
 Capsule content: Colloidal silicon, anhydrous; Crospovidone; Lactose monohydrate; Poloxamer; Magnesium stearate.
 Capsule shell: Gelatin; Titanium dioxide (E171); Iron oxide, red (E172); Iron oxide, yellow (E172).
 Printing ink: Shellac; Iron oxide, black (E172); Propylene glycol; Ammonium hydroxide

*TASIGNA (nilotinib capsules) 150 mg Hard Capsules:*
Each capsule contains 150 mg nilotinib base (as hydrochloride monohydrate).
White to yellowish powder in red opaque hard gelatin capsules, size 1 with black axial imprint “NVR/BCR”.

*Non-medicinal Ingredients:*
 Capsule content: Colloidal silicon, anhydrous; Crospovidone; Lactose monohydrate; Poloxamer 188; Magnesium stearate.
 Capsule shell: Gelatin; Titanium dioxide (E171); Iron oxide, red (E172), Iron oxide, yellow (E172).
 Printing ink: black (E172) iron oxide.

*TASIGNA (nilotinib capsules) 200 mg Hard Capsules:*
Each capsule contains 200 mg nilotinib base (as hydrochloride monohydrate).
White to yellowish powder in light yellow opaque hard gelatin capsules, size 0 with red axial imprint “NVR/TKI”.

*Non-medicinal Ingredients:*
 Capsule content: Colloidal silicon anhydrous; Crospovidone; Lactose monohydrate; Poloxamer 188; Magnesium stearate.
 Capsule shell: Gelatin; Titanium dioxide; Iron oxide, yellow.
 Printing ink: includes red iron oxide.

Availability of Dosage Forms:
TASIGNA (nilotinib capsules)
50 mg Capsules are supplied in blister packs (5 strips of 8 blisters/card, 3 cards/carton).

150 mg Capsules are supplied in blister packs (7 strips of 4 blisters/card, 4 cards/carton).

200 mg Capsules are supplied in blister packs (7 strips of 4 blisters/card, 4 cards/carton).
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Common name: Nilotinib hydrochloride monohydrate

Chemical name: 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-(3-pyridin-3-yl)pyrimidin-2-yl)amino]benzamide, monohydrochloride, monohydrate

Molecular formula:
- Salt form as monohydrate: $\text{C}_{28}\text{H}_{22}\text{F}_{3}\text{N}_{7}\text{O}.\text{HCl}.\text{H}_{2}\text{O}$
- Salt form on anhydrous basis: $\text{C}_{28}\text{H}_{22}\text{F}_{3}\text{N}_{7}\text{O}.\text{HCl}$
- Nilotinib base: $\text{C}_{28}\text{H}_{22}\text{F}_{3}\text{N}_{7}\text{O}$

Molecular mass:
- Salt form as monohydrate: 583.99
- Salt form on anhydrous basis: 565.98
- Nilotinib base: 529.52

Structural formula:

![Structural formula image]

Physicochemical properties:

Physical Description: White to slightly yellowish or slightly greenish yellowish powder.

Solubility: Solubility of nilotinib hydrochloride monohydrate in aqueous solutions strongly decreases with increasing pH, and that nilotinib hydrochloride monohydrate is practically insoluble in buffer solutions of pH 4.5 and higher pH values. Nilotinib hydrochloride monohydrate is very soluble.
in dimethyl sulfoxide, sparingly soluble in ethanol and methanol, very slightly soluble in acetonitrile and n-octanol.

**pH:** The pH value of a 0.02% solution of nilotinib hydrochloride monohydrate in water/ethanol 50:50 (V/V) was found to be 4.3. The pH value of a 0.1% suspension of nilotinib hydrochloride monohydrate in water was determined to be 5.3.

**pKa:** $pK_a_1 = 2.1$, and $pK_a_2 = 5.4$.

**Partition Coefficient:** The distribution coefficient for nilotinib hydrochloride monohydrate in n-octanol/0.1N HCl buffer at 37.0 ± 0.5°C was determined to be 0.08.

**Melting point:** Nilotinib hydrochloride monohydrate may undergo dehydration prior to melting, therefore no range can be defined.
CLINICAL TRIALS

Newly diagnosed Ph+ CML-CP (adults)

Study demographics and trial design

The clinical efficacy of nilotinib in newly diagnosed Ph+ CML-CP adult patients, has been demonstrated based on the Phase III Study (A2303). The design of the study is illustrated in Figure 1.

Figure 1.
Table 14  Summary of adult patient demographics for clinical trials (Newly diagnosed Ph+ CML-CP patients exposed to study drug)

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2303</td>
<td>Open label, multicenter, randomized Phase III study was conducted to determine the efficacy of TASIGNA versus GLEEVEC in adult patients with cytogenetically confirmed newly diagnosed Ph+ CML-CP.</td>
<td>nilotinib and imatinib were administered orally:</td>
<td>Total number of patients randomized = 846 imatinib 400 mg once daily (n=283) nilotinib 300 mg twice daily (n=282) nilotinib 400 mg twice daily (n=281) Median time on treatment was approximately 60 months in all three treatment groups.</td>
<td>imatinib 400 mg once daily 12.4% ≥ 65 years of age Mean: 47(18-80) nilotinib 300 mg twice daily 12.8% ≥ 65 years of age Mean: 47 (18-85) nilotinib 400 mg twice daily 10.0% ≥ 65 years of age in Mean: 47 (18-81)</td>
<td>imatinib 400 mg once daily M=55.8% F=44.2% nilotinib 300 mg twice daily M=56.0% F=44.0% nilotinib 400 mg twice daily M=62.3% F=37.7%</td>
</tr>
</tbody>
</table>

An open label, multicenter, randomized Phase III study (A2303) was conducted to determine the efficacy of TASIGNA versus imatinib in adult patients with cytogenetically confirmed newly diagnosed Ph+ CML-CP. Patients were within six months of diagnosis and were previously untreated for CML-CP, except for hydroxyurea and/or anagrelide (See Table 15). In addition, patients were stratified according to Sokal risk score at time of diagnosis.

Baseline characteristics were well balanced between the groups (Table 14). There were slightly more male than female patients in all groups. More than 60% of all patients were Caucasian, and 25% were Asian. Table 15 displays the disease history characteristics.

The primary data analysis time point was when all 846 patients completed 12 months of treatment (or discontinued earlier). Subsequent analyses reflect when patients completed 24, 36, 48 and 60 months of treatment (or discontinued earlier). The median time on treatment is approximately 60 months in all three treatment groups.

The median actual dose intensity was 400 mg/day in the imatinib group, 593 mg/day in the nilotinib 300 mg twice daily group. This study is on-going. Table 16 displays the duration of exposure with TASIGNA.
Table 15  CML Disease History Characteristics

<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 300 mg twice daily N=282</th>
<th>Imatinib 400 mg once daily N=283</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median time since diagnosis of CML in days (range)</td>
<td>31.0 (0-182)</td>
<td>28.0 (1-183)</td>
</tr>
<tr>
<td>Hydroxyurea</td>
<td>216 (76.6%)</td>
<td>201 (71.0%)</td>
</tr>
<tr>
<td>Anagrelide</td>
<td>6 (2.1%)</td>
<td>4 (1.4%)</td>
</tr>
</tbody>
</table>

Table 16  Duration of Exposure with TASIGNA

<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 300 mg twice daily N=279</th>
<th>Imatinib 400 mg once daily N=277</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median duration of therapy in months (95%CI)</td>
<td>60.02 (59.20-60.42)</td>
<td>58.69 (52.21-59.99)</td>
</tr>
</tbody>
</table>

Study Results:

Primary Efficacy Endpoint: Major Molecular Response (MMR)

The primary efficacy variable was MMR at 12 months after the start of study medication. MMR was defined as ≤ 0.1% BCR-ABL/ABL % by international scale measured by Real-Time Quantitative PCR (RQ-PCR), which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline.

The primary efficacy endpoint, MMR rate at 12 months was statistically significantly superior in the nilotinib 300 mg twice daily group compared to the imatinib 400 mg once daily group (44.3% vs. 22.3%, p<0.0001) (Table 17).

At the nilotinib recommended dose of 300 mg twice daily, the rates of MMR at 3, 6, 9 and 12 months was 8.9%, 33.0%, 43.3% and 44.3%, respectively. In the imatinib 400 mg once daily group, the rates of MMR at 3, 6, 9 and 12 months was 0.7%, 12.0%, 18.0% and 22.3%.

The MMR rates at 12, 24, 36, 48, and 60 months is presented in Table 17.
<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 300 mg twice daily</th>
<th>Imatinib 400 mg once daily</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=282*</td>
<td>N=283*</td>
</tr>
<tr>
<td>number (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>MMR at 12 months²</td>
<td>125(44.3)</td>
<td>63(22.3)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[38.4, 50.3]</td>
<td>[17.6, 27.6]</td>
</tr>
<tr>
<td>MMR at 24 months²</td>
<td>174 (61.7)</td>
<td>106 (37.5)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[55.8, 67.4]</td>
<td>[31.8, 43.4]</td>
</tr>
<tr>
<td>MMR at 36 months²</td>
<td>165 (58.5)</td>
<td>109 (38.5)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[52.5, 64.3]</td>
<td>[32.8, 44.5]</td>
</tr>
<tr>
<td>MMR at 48 months²</td>
<td>169 (59.9)</td>
<td>124 (43.8)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[54.0, 65.7]</td>
<td>[38.0, 49.8]</td>
</tr>
<tr>
<td>MMR at 60 months²</td>
<td>177 (62.8)</td>
<td>139 (49.1)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[56.8, 68.4]</td>
<td>[43.2, 55.1]</td>
</tr>
</tbody>
</table>

1 Denominator for this analysis (N) includes all randomized patients, whether evaluable or not evaluable for MMR

1 CMH test p-value for response rate (vs. Imatinib 400 mg) <0.0001

2 Only patients who were in MMR at a specific time point are included as responders for that time point. Other randomized patients, whether evaluable or not at that time point, are conservatively considered as not MMR:
- A total of 129 (15.2%) of all patients were not evaluable for MMR at 12 months (40 in the nilotinib 300 mg BID group, 41 in the nilotinib 400 mg BID group and 48 in the imatinib group) due to missing/not evaluable PCR assessments (n=3), atypical transcripts at baseline (n=8), or discontinuation prior to the 12-month time point (n=118).
- A total of 211 (24.9%) of all patients were not evaluable for MMR at 24 months (68 in the nilotinib 300 mg BID group, 61 in the nilotinib 400 mg BID group and 82 in the imatinib group) due to missing/not evaluable PCR assessments (n=13), atypical transcripts at baseline (n=8), or discontinuation prior to the 24-month time point (n=190).
- A total of 199 (35.2%) of all patients were not evaluable for MMR at 36 months (87 in the nilotinib 300 mg BID group and 112 in the imatinib group) due to missing/not evaluable PCR assessments (n=17), atypical transcripts at baseline (n=7), or discontinuation prior to the 36-month time point (n=175).
- A total of 305 (36.1%) of all patients were not evaluable for MMR at 48 months (98 in the nilotinib 300 mg BID group, 88 in the nilotinib 400 mg BID group and 119 in the imatinib group) due to missing/not evaluable PCR assessments (n=18), atypical transcripts at baseline (n=8), or discontinuation prior to the 48-month time point (n=279).
- A total of 322 (38.1%) of all patients were not evaluable for MMR at 60 months (99 in the nilotinib 300 mg BID group, 93 in the nilotinib 400 mg BID group and 130 in the imatinib group) due to missing/not evaluable PCR assessments (n=9), atypical transcripts at baseline (n=8), or discontinuation prior to the 60-month time point (n=305).
MMR rates by different time points (including patients who achieved MMR at or before those time points as responders) are presented in the cumulative incidence of MMR (Figure 2).

**Figure 2** Cumulative Incidence of MMR

For all Sokal risk groups, the MMR rates at all time points remained consistently higher in the 300 mg twice daily nilotinib group than in the imatinib group.

In an exploratory analysis, 91% (234/258) of patients on nilotinib 300 mg twice daily achieved BCR-ABL levels ≤10% at 3 months of treatment compared to 67% (176/264) of patients on imatinib 400 mg once daily.

Based on the Kaplan-Meier analyses of time to first MMR among all patients, the probability of achieving MMR at different time points was higher in the nilotinib group compared to the imatinib group (hazard ratio/HR=2.20 and stratified log-rank \( p < 0.0001 \) between nilotinib 300 mg twice daily and imatinib).
Patients categorized according to their best overall BCR-ABL ratio achieved are summarized in Table 18 above.

The proportions of patients who had a molecular response of $\leq 0.01\%$ and $\leq 0.0032\%$ by International Scale (IS) at different time-points is presented in Table 19.

### Table 18  Best overall BCR-ABL ratio rates (by 60 months cut-off) – Study CAMN107A2303 (FAS)

<table>
<thead>
<tr>
<th>BCR-ABL ratio categories$^1$</th>
<th>TASIGNA 300 mg twice daily N=282</th>
<th>Imatinib 400 mg once daily N=283</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\leq 0.0032%$</td>
<td>156 (55.3%)</td>
<td>92 (32.5%)</td>
</tr>
<tr>
<td>$&gt;0.0032% - \leq 0.01%$</td>
<td>31 (11%)</td>
<td>28 (9.9%)</td>
</tr>
<tr>
<td>$&gt;0.01 - \leq 0.1%$</td>
<td>31 (11%)</td>
<td>53 (18.7%)</td>
</tr>
<tr>
<td>$&gt;0.1 - \leq 1%$</td>
<td>28 (9.9%)</td>
<td>43 (15.2%)</td>
</tr>
<tr>
<td>$&gt;1 - \leq 10%$</td>
<td>15 (5.3%)</td>
<td>26 (9.2%)</td>
</tr>
<tr>
<td>$&gt;10%$</td>
<td>12 (4.3%)</td>
<td>32 (11.3%)</td>
</tr>
</tbody>
</table>

1Molecular response of $>0.01 - \leq 0.1\%$, $>0.0032 - \leq 0.01\%$ and $\leq 0.0032\%$ by International Scale (IS) corresponds to a $\geq 3$ log to $<4$ log reduction; a $\geq 4$ log to $<4.5$ log reduction and $\geq 4.5$ log reduction, respectively, of BCR-ABL transcripts from a standardized baseline.

### Table 19  Proportions of patients who had molecular response of $\leq 0.01\%$ (4 log reduction and $\leq 0.0032\%$ (4.5 log reduction)

<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 300 mg twice daily (%)</th>
<th>Imatinib 400 mg once daily (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\leq 0.01%$</td>
<td>11.7</td>
<td>3.9</td>
</tr>
<tr>
<td>$\leq 0.0032%$</td>
<td>4.6</td>
<td>0.4</td>
</tr>
<tr>
<td>At 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 24 months</td>
<td>24.5</td>
<td>10.2</td>
</tr>
<tr>
<td>At 36 months</td>
<td>29.4</td>
<td>14.1</td>
</tr>
<tr>
<td>At 48 months</td>
<td>33.0</td>
<td>19.8</td>
</tr>
<tr>
<td>At 60 months</td>
<td>47.9</td>
<td>31.1</td>
</tr>
</tbody>
</table>
**Duration of MMR**

Based on Kaplan-Meier estimates of the duration of first MMR, the proportions of patients who achieved MMR and were maintaining response for 60 months among patients who achieved MMR were 93.4% (95% CI: 89.9% to 96.9%) in the nilotinib 300 mg twice daily group, and 89.1% (95% CI: 84.2% to 94.0%) in the imatinib 400 mg once daily group.

**Secondary Efficacy Endpoint: Complete Cytogenetic Response (CCyR)**

CCyR was defined as 0% Ph+ metaphases in the bone marrow based on a minimum of 20 metaphases evaluated. CCyR rate by 12 months (includes patients who achieved CCyR at or before the 12 month time point as responders) was statistically higher for the nilotinib 300 mg twice daily group compared to imatinib 400 mg once daily group, Table 20.

CCyR rate by 24 months (includes patients who achieved CCyR at or before the 24 month time point as responders) was statistically higher for the nilotinib 300 mg twice daily group compared to imatinib 400 mg once daily group (Table 20).

**Table 20**

<table>
<thead>
<tr>
<th></th>
<th>TASIGNA 300 mg twice daily</th>
<th>Imatinib 400 mg once daily</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=282</td>
<td>N=283</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td><strong>By 12 months</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete Cytogenetic Response</td>
<td>226 (80.1)</td>
<td>184 (65.0)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[75.0,84.6]</td>
<td>[59.2,70.6]</td>
</tr>
<tr>
<td>CMH test p-value for response rate (vs. imatinib 400 mg)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>By 24 months</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete Cytogenetic Response</td>
<td>245 (86.9)</td>
<td>218 (77.0)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[82.4, 90.6]</td>
<td>[71.7, 81.8]</td>
</tr>
<tr>
<td>CMH test p-value for response rate (vs. Imatinib 400 mg)</td>
<td>0.0018</td>
<td></td>
</tr>
</tbody>
</table>

CMH: Cochran-Mantel-Haenszel

Cytogenetic assessments after 24 months follow-up were not required
Duration of CCyR

Based on Kaplan-Meier estimates, the proportions of patients were maintaining response for 60 months among patients who achieved CCyR were 99.1% (95% CI: 97.9% to 100%) in the nilotinib 300 mg twice daily group, and 97.0% (95% CI: 94.7% to 99.4%) in the imatinib 400 mg once daily group.

Secondary Efficacy Endpoint: Progression to accelerated phase and blast crisis (AP/BC) on study

Progression “on study” refers to the first documented disease progression to AP/BC or CML-related death that occurred at any time after randomization, up to a 60 month post-treatment follow-up cut-off. Patients receiving nilotinib 300 mg twice daily who had responded insufficiently to study treatment were allowed to increase the dose. Patients receiving imatinib who had responded insufficiently to study treatment were allowed to cross over to nilotinib. By 60 months, in the intention-to-treat (ITT) population, 31 patients progressed to AP/BC (21 in the imatinib group and 10 in the nilotinib 300 mg twice daily group). The estimated rates of patients free from progression to AP/BC at 60 months were 92.1% in the imatinib group and 96.3% in the nilotinib 300 mg twice daily group (HR=0.4636 between nilotinib 300 mg twice daily group and imatinib).

BCR-ABL Mutations

Study A2303 excluded patients with the BCR-ABL T315I mutation at baseline. In this study, BCR-ABL mutation analysis was performed at baseline and post-treatment. Post-treatment mutation analysis was performed only in a subset of patients when warranted by their clinical course. At baseline, no BCR-ABL mutations were detected for any of the 846 patients enrolled in Study A2303. However, Abl polymorphisms were identified at baseline in some patients with equal distribution among the three treatment arms (23 for nilotinib 300 mg twice daily, 20 for nilotinib 400 mg twice daily, and 17 for imatinib). ABL polymorphism were confirmed by amplifying and sequencing the kinase domain region of both non-translocated ABL alleles in the same samples. Polymorphisms have been reported to have no clinical relevance.

At the 60 month follow-up, 12 patients in the nilotinib 300 mg twice daily arm developed mutations, and 10 of the 12 had at least one of the following mutations: T315I, Y253H, E255K, or F359V mutations. One of the 12 patients in the nilotinib 300 mg twice daily arm with E459K mutation progressed. Eleven patients in the nilotinib 400 mg twice daily arm developed mutations, and 2 patients progressed. All 11 patients had one of the following mutations: T315I, Y253H, E255K/V, F359V or Q252H mutations. Twenty-two patients in the imatinib arm developed mutations, and 8 of 22 had one of the following mutations: T315I, Y253H or F359V/C/I or M244V mutations.

The T315I mutation confers a high level of resistance to nilotinib and most tyrosine kinase inhibitors and is associated with rapid disease progression. The Y253H, E255K/V and F359V/C/I mutations are known to be less sensitive to nilotinib.
Secondary Efficacy Endpoint: Overall survival (OS)

A total of 50 patients died on study, during core treatment, extension treatment or during the follow-up after discontinuation of treatment (18 in the nilotinib 300 mg twice daily group, 10 in the nilotinib 400 mg twice daily group, and 22 in the imatinib 400 mg once daily group). The estimated rates of patients alive at 60 months were 93.7%, versus 91.7%, \((p = 0.4881\) between nilotinib 300 mg twice daily and imatinib) and 96.2% versus 91.7\% \((p= 0.0266\) between nilotinib 400 mg twice daily and imatinib). As of the 60 month cutoff date, no overall survival benefit has been demonstrated.

Resistant or intolerant Ph+ CML in chronic phase and accelerated phase (adults)

Study demographics and trial design

The clinical efficacy of nilotinib in imatinib-resistant or -intolerant Ph+ CML in chronic phase (CP) or in accelerated phase (AP) adult patients, has been demonstrated based on the Phase II component of Study (A2101).

The design of Study A2101 is illustrated in Figure 3 below.
An open label, multicenter, Phase II study (A2101) was conducted to determine the efficacy of TASIGNA in patients with imatinib-resistant or -intolerant CML with separate treatment arms for chronic and accelerated phase CML. The study is ongoing. Efficacy was based on 321 CML-CP patients and 137 CML-AP patients enrolled. Median duration of treatment was 561 days and 264 days, respectively (see Table 22). TASIGNA was administered on a continuous basis (twice daily 2 hours after a meal and no additional food for at least one hour), unless there was evidence of inadequate response or disease progression (see Table 21). Dose escalation to 600 mg twice daily was allowed (see Table 21). A total of 57 CML-CP and 33 CML-AP patients were escalated to the 600 mg twice daily dose.

Table 22  Duration of Exposure with TASIGNA

<table>
<thead>
<tr>
<th>Metric</th>
<th>Chronic Phase CML</th>
<th>Accelerated Phase CML</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median duration of therapy in days (95% CI)</td>
<td>561 (459-680)</td>
<td>264 (190-357)</td>
</tr>
</tbody>
</table>
Study Results:

Resistance to imatinib included failure to achieve a complete hematologic response (by 3 months), cytogenetic response (by 6 months) or major cytogenetic response (by 12 months) or progression of disease after a previous cytogenetic or hematologic response. Imatinib intolerance included patients who discontinued imatinib because of toxicity and were not in major cytogenetic response at time of study entry.

Overall, 70% of CML-CP patients were imatinib-resistant while 30% were imatinib-intolerant. Overall, 80% of CML-AP patients were imatinib-resistant while 20% were imatinib-intolerant. Prior treatment included imatinib, hydroxyurea, interferon, and stem cell transplant (Table 23). The median highest prior imatinib dose had been 600 mg/day for CP and AP patients. The highest prior imatinib dose was ≥ 600 mg/day in 72% of all CML-CP patients and 79% of all CML-AP patients. Thirty-eight (38%) of all CML-CP patients and 45% of all CML-AP patients received imatinib doses ≥800 mg/day.

Table 23 CML Disease History Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Chronic Phase (n = 321)</th>
<th>Accelerated Phase (n = 137)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median time since diagnosis in months (range)</td>
<td>58 (5-275)</td>
<td>71 (2-298)</td>
</tr>
<tr>
<td>Imatinib Resistant without MCyR</td>
<td>226 (70%)</td>
<td>-</td>
</tr>
<tr>
<td>Imatinib Intolerant without MCyR</td>
<td>95 (30%)</td>
<td>27 (20%)</td>
</tr>
<tr>
<td>Median time of imatinib treatment in days 95%CI</td>
<td>975 (892-1068)</td>
<td>857 (702-1059)</td>
</tr>
<tr>
<td>Prior hydroxyurea</td>
<td>83%</td>
<td>91%</td>
</tr>
<tr>
<td>Prior interferon</td>
<td>58%</td>
<td>50%</td>
</tr>
<tr>
<td>Prior organ transplant</td>
<td>7%</td>
<td>8%</td>
</tr>
</tbody>
</table>

* One patient had missing information for imatinib-resistant/intolerant status

The primary endpoint in the CP patients was major cytogenetic response (MCyR), defined as elimination (complete cytogenetic response, CCyR) or significant reduction to <35% Ph+
metaphases (partial cytogenetic response, PCyR) of Ph+ hematopoietic cells. The secondary endpoint was complete hematologic response (CHR) in CP patients.

The primary endpoint in the AP patients was overall confirmed hematologic response (HR), defined as either a complete hematologic response (CHR), or no evidence of leukemia (NEL).

**Chronic Phase:** The MCyR rate in 321 CP patients was 59%. Most responders achieved their MCyR rapidly within 3 months (median 2.8 months) of starting TASIGNA treatment and these responses were sustained. The CCyR rate was 44%. The median time to achieve CCyR was just past 3 months (median 3.3 months). Of the patients who achieved MCyR, 77% (95% CI: 71% to 84%) were maintaining response at 24 months. Median duration of MCyR has not been reached. Of the patients who achieved CCyR, 84% (95% CI: 77% to 91%) were maintaining response at 24 months. Median duration of CCyR has not been reached. Patients with a CHR at baseline achieved a MCyR faster (1.4 vs. 2.8 months). Of CP patients without a baseline CHR, 76% achieved a CHR, median time to CHR was 1 month. Median duration of CHR has not been reached. The response rates for the CP treatment arm are reported in Table 24 and Figure 4.

The estimated 24-month overall survival rate in CML -CP patients was 87%.

**Accelerated Phase:** The overall confirmed HR rate in 137 AP patients, was 44%. Median duration of confirmed HR was 21.5 months. Of the patients who achieved HR, 50% (95% CI: 35% to 65%) were maintaining response at 24 months. The rate of confirmed CHR was 31%. Median duration of confirmed CHR was 26.3 months. Of the patients who achieved CHR, 51% (95% CI: 34% to 69%) were maintaining response at 24 months. The unconfirmed MCyR rate was 32% with a median time to response of 2.8 months. Of the patients who achieved MCyR, 66% (95% CI: 50% to 82%) were maintaining response at 24 months. Median duration of MCyR has not been reached. The response rates for the AP treatment arm are reported in Table 24.

The estimated 24-month overall survival rate in CML -AP patients was 70%.

**Table 24** Responses in CML – adults

<table>
<thead>
<tr>
<th>(Best Response Rate)</th>
<th>Chronic Phase</th>
<th></th>
<th>Accelerated Phase</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intolerant (n = 95)</td>
<td>Resistant (n = 226)</td>
<td>Total (n = 321)</td>
<td>Intolerant (n = 27)</td>
</tr>
<tr>
<td>Hematologic Response (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall (95%CI)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>52 (32-71)</td>
</tr>
<tr>
<td>CHR (95%CI)</td>
<td>90%1 (79-97)</td>
<td>72%1 (64-79)</td>
<td>76%1,2 (70-82)</td>
<td>372</td>
</tr>
<tr>
<td>NEL</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>152</td>
</tr>
</tbody>
</table>

Unconfirmed1 Cytogenetic Response (%)
Major (95%CI) Complete Partial

<table>
<thead>
<tr>
<th></th>
<th>66% (56-76)</th>
<th>56% (49-63)</th>
<th>59% (54-65)</th>
<th>41 (22-61)</th>
<th>30 (22-40)</th>
<th>32 (24-41)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete</td>
<td>51</td>
<td>41</td>
<td>44</td>
<td>30</td>
<td>19</td>
<td>21</td>
</tr>
<tr>
<td>Partial</td>
<td>16</td>
<td>15</td>
<td>15</td>
<td>11</td>
<td>11</td>
<td>11</td>
</tr>
</tbody>
</table>

CHR = Complete hematologic response   CcCyR = Complete cytogenetic response  
NEL = No evidence of leukemia

**Hematologic response:** CHR+NEL  
CHR (CML-CP): WBC <10 x 10^9/L, platelets <450,000/mm^3, no blasts or promyelocytes in peripheral blood, myelocytes + metamyelocytes <5% in peripheral blood, basophils <5% in peripheral blood, and no extramedullary involvement.  
CHR (CML-AP): neutrophils ≥ 1.5 x 10^9/L, platelets ≥ 100 x 10^9/L, no myeloblasts in peripheral blood, myeloblast < 5% in bone marrow, basophils <5% in peripheral blood, and no extramedullary involvement.  
NEL: same criteria as for CHR but neutrophils ≥ 1.0 x 10^9/L, platelets ≥ 20 x 10^9/L without platelet transfusion or bleeding and no requirement for basophils.

**Cytogenetic response:** Complete (0% Ph+ metaphases) or partial (1-35%). Cytogenetic responses were based on the percentage of Ph-positive metaphases among ≥ 20 metaphase cells in each bone marrow sample.  
^Unconfirmed: Response based on one assessment  
^Confirmed: Response assessments confirmed by another assessment at least after 4 weeks).

^207 CP patients did not have a CHR at baseline and were therefore assessable for complete hematologic response of which 158 patients (76%) achieved a CHR.

**Figure 4** Kaplan-Meier estimates of duration of MCyR (months)^1 among CML-CP patients who achieved MCyR - Study CAMN107A2101E2 (Conventional ITT population)

^1Duration defined as time between first documented response to the date of discontinuation due to progression of disease or death.

Separate treatment arms were also included in the Phase II study (A2101) to study TASIGNA in a group of CP and AP patients who had been extensively pre-treated with multiple therapies,
including a tyrosine kinase inhibitor agent in addition to imatinib. Of these patients, 30/36 (83%) were treatment-resistant. In 22 CP patients evaluated for efficacy, TASIGNA induced a 32% MCyR rate and a 50% CHR rate.

After imatinib failure, 24 different BCR-ABL mutations at baseline were noted in 42% of chronic phase and 54% of accelerated phase CML patients who were evaluated for mutations. TASIGNA demonstrated efficacy in patients harboring a variety of BCR-ABL mutations associated with imatinib resistance, except T315I.

**Treatment discontinuation in newly diagnosed Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5)**

**Table 25 Overview of Treatment Free Remission (TFR) clinical study I2201**

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>I2201</td>
<td>Phase II, single-arm, multicenter, study of TFR in patients with Ph+ CML-CP who have achieved sustained MRD* status on first-line nilotinib treatment.</td>
<td>Dose: 300 mg nilotinib twice daily. Dose regimen was decreased to 400 mg once daily if patients did not tolerate the planned dose. Duration of treatment consolidation phase: 52 weeks. Duration of TFR phase: median=76 weeks as of 96-week data cut-off.</td>
<td>Total: 215 patients started the consolidation phase of the study 190 patients entered the TFR phase.</td>
<td>Total: 215 Age: 54 (21-86) years 20.5% over age 65 TFR Phase: 190 Age: 54 (21-86) years 21.1% over age 65</td>
<td>Total: 215 M: 113 (52.6%) F: 102 (47.4%) TFR Phase: 190 M: 96 (50.5%) F: 94 (49.5%)</td>
</tr>
</tbody>
</table>

*Sustained minimal residual disease (MRD) is defined as the following results from the last 4 quarterly PCR assessments: MR4.5 at last assessment, no assessment worse than MR4.0 and less than 2 assessments between MR4 and MR4.5.

In an open-label, multicenter, single-arm study, 215 adult patients with Ph+ CML-CP treated with TASIGNA in first-line for ≥ 2 years who achieved MR4.5 as measured with a quantitative diagnostic test validated with a sensitivity of at least MR4.5 (BCR-ABL/ABL ≤0.0032% IS) were enrolled to continue TASIGNA treatment for an additional 52 weeks (TASIGNA consolidation phase). Of the 215 patients, 190 patients (88.4%) entered the TFR phase after achieving a sustained molecular response (MR4.5) during the consolidation phase, defined by the following criteria:
• The last four quarterly assessments (taken every 12 weeks) were at least MR4.0 (BCR-ABL/ABL ≤ 0.01% IS), and maintained for 1 year
• The last assessment being MR4.5 (BCR-ABL/ABL ≤ 0.0032% IS)
• No more than two assessments falling between MR4.0 and MR4.5 (0.0032% IS < BCR-ABL/ABL ≤ 0.01% IS).

The median age of patients who entered the TFR phase was 55 years, 49.5% were females, and 21.1% of the patients were ≥ 65 years of age. The median actual dose intensity during the 52-week TASIGNA consolidation phase was 600.0 mg/day.

BCR-ABL levels were monitored every 4 weeks during the first 48 weeks of the TFR phase. Monitoring frequency was intensified to every 2 weeks upon the loss of MR4.0. Biweekly monitoring ended at one of the following time points:

• Loss of MMR requiring patient to re-initiate TASIGNA treatment
• When the BCR-ABL levels returned to a range between MR4.0 and MR4.5
• When the BCR-ABL levels remained lower than MMR for 4 consecutive measurements (8 weeks from initial loss of MR4.0).

Any patient with loss of MMR during the TFR phase re-initiated TASIGNA treatment at 300 mg twice daily or at a reduced dose level of 400 mg once daily if required from the perspective of tolerance, within 5 weeks after the collection date of the blood sample demonstrating loss of MMR. Patients who required re-initiation of TASIGNA treatment were monitored for BCR-ABL levels every 4 weeks for the first 24 weeks and then every 12 weeks thereafter in patients who regained MMR.

The primary endpoint was the percentage of patients who were in MMR at 48 weeks after starting the TFR phase (considering any patient who required re-initiation of treatment before 48 weeks as non-responder). Of the 190 patients who entered the TFR phase, 98 patients (51.6% [95% CI: 44.2, 58.9]) were in MMR in the TFR phase at 48 weeks and 93 patients (48.9%, [95% CI: 41.6, 56.3]) were in MMR in the TFR phase at 96 weeks.

By the 96-week analysis data cut-off date, 91 patients (47.9%) discontinued from the TFR phase due to loss of MMR, and 1 (0.5%), 1 (0.5%), 1 (0.5%) and 3 patients (1.6%) due to death from unknown cause, physician decision, lost to follow-up, and subject decision, respectively. Among the 91 patients who discontinued the TFR phase due to loss of MMR, 88 patients restarted TASIGNA treatment and 3 patients permanently discontinued from the study.

Of the 88 patients who restarted treatment due to loss of MMR in the TFR phase, 87 patients (98.9%) regained MMR (one patient discontinued study permanently due to subject decision after 7.1 weeks of retreatment without regaining MMR) and 81 patients (92.0%) regained MR4.5 by the time of the 96 week cut-off date.

The time by which 50% of all retreated patients regained MMR and MR4.5 in the retreatment phase was 7.0 and 13.1 weeks, respectively. The cumulative rate of MMR and MR4.5 regained at 24 weeks since treatment re-initiation was 97.7% (86/88 patients) and 86.4% (76/88 patients), respectively.
Among the 190 patients in the TFR phase, 98 patients had a treatment-free survival (TFS) event (defined as discontinuation from TFR phase due to any reason, loss of MMR, death due to any cause, progression to AP/BC up to the end of TFR phase, or re-initiation of treatment due to any cause in the study) by the 96-week cut-off date. At 96 weeks, the KM estimated median TFS was 74.6 weeks (95% CI: 36.0, NE) where NE is not estimable, and the KM-estimated 96 weeks TFS rate was 48.9% (95% CI: 41.7, 55.8) (Figure 5).

**Figure 5** Kaplan-Meier estimate of treatment-free survival after start of TFR (Full Analysis Set)*

*By the time of the 96-week data cut-off date, one single patient lost MMR at week 120, at the time when only 8 patients were considered at risk. This explains the artificial drop at the end of the curve.

Treatment discontinuation in Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5) on TASIGNA following prior imatinib therapy
Table 26  Overview of Treatment Free Remission (TFR) clinical study A2408

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and median duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
</table>
| A2408   | Phase II, single arm, multicenter study of TFR in Ph+ CML-CP patients after achieving sustained MR4.5 on nilotinib | **Dose:** Nilotinib: 300 mg or 400 mg twice daily, 400 mg once daily or any other dose received prior to study entry  
  Duration of treatment consolidation phase: 52 weeks  
  Duration of treatment-free remission phase: median=99 weeks as of 96-week data cut-off. | Total: 163 patients started the consolidation phase of the study  
126 patients entered the TFR phase | Total 163  
Age 56.43 (21-86) years  
24.5% over age 65.  
TFR Phase: 126  
Age 55 (21-86 years)  
27.8% over age 65. | Total: 163  
M: 77 (47.2%)  
F: 86 (52.8%)  
TFR Phase: 126  
M: 56 (44.4%)  
F: 70 (55.6%) |

In an open-label, multicenter, single-arm study, 163 adult patients with Ph+ CML-CP taking tyrosine kinase inhibitors (TKIs) for ≥3 years (imatinib as initial TKI therapy for more than 4 weeks without documented MR4.5 on imatinib at the time of switch to TASIGNA, then switched to TASIGNA for at least 2 years), and who achieved MR4.5 on TASIGNA treatment as measured with a quantitative diagnostic test validated with a sensitivity of at least MR4.5 ($BCR-ABL/ABL \leq 0.0032\%\ IS$) were enrolled to continue TASIGNA treatment for an additional 52 weeks (TASIGNA consolidation phase). Of the 163 patients, 126 patients (77.3%) entered the TFR phase after achieving a sustained molecular response (MR4.5) during the consolidation phase, defined by the following criterion:

- The last four quarterly assessments (taken every 12 weeks) showed no confirmed loss of MR4.5 ($BCR-ABL/ABL \leq 0.0032\%\ IS$) during 1 year.

The median age of patients who entered the TFR phase was 56 years, 55.6% were females, and 27.8% of the patients were ≥65 years of age. The median actual dose intensity during the 52-week TASIGNA consolidation phase was 771.8 mg/day with 52.4%, 29.4%, 0.8%, 16.7% and 0.8% of patients receiving a daily TASIGNA dose of 800 mg, 600 mg, 450mg, 400mg and 300mg just before entry into the TFR phase, respectively.

Patients who entered the TFR phase but experienced two consecutive measurements of $BCR-ABL/ABL > 0.01\%\ IS$ were considered having a confirmed loss of MR4.0, triggering re-initiation of TASIGNA treatment. Patients with loss of MMR in the TFR phase immediately restarted TASIGNA treatment without confirmation. All patients who restarted TASIGNA therapy had $BCR-ABL$ transcript levels monitored every 4 weeks for the first 24 weeks, then once every 12 weeks.
The primary endpoint was defined as the proportion of patients without confirmed loss of MR4.0 or loss of MMR within 48 weeks following discontinuation of TASIGNA therapy. Of the 126 patients who entered the TFR phase, 73 patients (57.9%, [95% CI: 48.8, 66.7]) did not have loss of MMR, or confirmed loss of MR4.0, or re-initiation of TASIGNA therapy within 48 weeks, and in 67 patients (53.2% [95% CI: 44.1, 62.1]) within 96 weeks after the start of the TFR phase.

By the 96-weeks analysis data cut-off date, 61 patients (48.4%) discontinued from the TFR phase: 58 patients (46.0%) due to loss of MMR or confirmed loss of MR4.0, 2 patients (1.6%) due to subject/guardian decision and one patient (0.8%) due to pregnancy. Among the 58 patients who discontinued from the TFR phase due to confirmed loss of MR4.0 or loss of MMR, 56 patients restarted TASIGNA therapy and 2 patients permanently discontinued from the study. Of the 56 patients who restarted TASIGNA treatment due to confirmed loss of MR4.0 or loss of MMR in the TFR phase, 52 patients (92.9%) regained MR4.0 and MR4.5; 4 patients (7.1%) did not regain MR4.0 by the time of the cut-off date.

The time by which 50% of all retreated patients regained MR4.0 and MR4.5 in the retreatment phase was 12 weeks and 13.1 weeks respectively. The cumulative rate of MR4.0 and MR4.5 regained by 48-weeks since treatment re-initiation, was 92.9% (52/56 patients) and 91.1% (51/56 patients), respectively.

Among the 126 patients in the TFR phase, 61 patients (48.4%) had a treatment-free survival (TFS) event (defined as discontinuation from TFR phase due to any reason, loss of MMR, confirmed loss of MR4.0, death due to any cause, progression to AP/BC up to the end of TFR phase, or re-initiation of treatment due to any cause in the study) on or before the 96-month cut-off date. At 96 weeks, the KM estimated median TFS was 111.0 weeks (95% CI: 27.9, NE) where NE is not estimable, and the KM-estimated TFS rate was 54.0% (95% CI: 44.9, 62.2) (Figure 6).
Table 27 Summary of pediatric patient demographics for clinical trials
(Newly diagnosed and resistant / intolerant Ph+ CML-CP patients exposed to TASIGNA)

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and median duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAMN107A</td>
<td>A multi-centre, open label, non-controlled Phase II study to evaluate the efficacy and safety of oral nilotinib in pediatric patients (1 to &lt;18 years old) with newly diagnosed Ph+ chronic myeloid leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistant or intolerant to either imatinib or dasatinib</td>
<td>50mg, 150mg and 200 mg capsules 230 mg/m² twice daily. Median time on treatment: Resistant/intolerant CML-CP: 15.6 months Newly diagnosed CML-CP: 14.6 months</td>
<td>Total: 58 Patients Resistant/ intolerant CML-CP: 33 patients Newly diagnosed CML-CP: 25 Patients</td>
<td>Imatinib/dasatinib resistant/intolerant CML-CP patients. Mean 12.4 (2-17) 2 to &lt;12 years: 12(36.4%) 12 to &lt;18 years: 21 (63.6%) Newly diagnosed CML-CP patients Mean 13.2 (10-16) 2 to 12 years: 6 (24.0%) 12 to &lt;18 years: 19 (76.0%)</td>
<td>Imatinib/dasatinib resistant/intolerant CML-CP patients. M: 21 (63.6%) F: 12 (36.4%) Newly diagnosed CML-CP patients M: 13 (52.0%) F: 12 (48.0%)</td>
</tr>
</tbody>
</table>
Pediatric patients with newly diagnosed Ph+ CML-CP or resistant/ intolerant Ph+ CML-CP

The safety and efficacy of nilotinib in pediatric patients with Ph+ CML-CP have been investigated in two open-label single arm studies (Phase 1, CAMN107A2120 and Phase 2 CAMN107A2203). The data presented here are from a pooled analysis of final data from CAMN107A2120 and data with cut-off date of 01-Jun-2016 (all patients had completed 12 x 28-day cycles or discontinued) from CAMN107A2203. A total of 69 pediatric patients (from 2 to <18 years of age) with either newly diagnosed chronic phase (CP) Ph+ CML, with CP or accelerated phase (AP) Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or with refractory/relapsed Ph+ ALL received nilotinib at a dose of 230 mg/m² twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg), approximately 12 hours apart.

In the pooled CML patient population (N=69), the median actual dose intensity was 435.5 mg/m²/day (range: 149 to 517 mg/m²/day), and the median relative dose intensity was 94.7% (range: 32 to 112%). Forty patients (58.0%) had relative dose intensity above 90%. The median time on treatment with nilotinib was 13.80 months (range: 0.7 to 30.9 months).

**Study Results**

In the resistant or intolerant CML patients (N=44), the primary efficacy endpoint, major molecular response (MMR; BCR-ABL/ABL ≤0.1% IS) rate at 6 cycles, was 34.1% (95% CI: 20.5, 49.9) with 15 patients being in MMR.

In the newly diagnosed CML patients (N=25), the two primary efficacy endpoints were MMR rate by 12 cycles and CCyR rate at 12 cycles. The MMR rate by 12 cycles was 64.0% (95% CI: 42.5, 82.0), with 16 patients achieving MMR and the CCyR rate at 12 cycles was 64.0% (95% CI: 42.5, 82.0) with 16 patients achieving CCyR.
Table 28  Rate of Major Molecular Response*

<table>
<thead>
<tr>
<th></th>
<th>Resistant or intolerant CML patients N=44</th>
<th>Newly diagnosed CML patients N=25</th>
</tr>
</thead>
<tbody>
<tr>
<td>At 6 cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>15 (34.1)</td>
<td>13 (52.0)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[20.5, 49.9]</td>
<td>[31.3, 72.2]</td>
</tr>
<tr>
<td>At 12 cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>18 (40.9)</td>
<td>15 (60.0)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[26.3, 56.8]</td>
<td>[38.7, 78.9]</td>
</tr>
<tr>
<td>By 12 cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>21 (47.7)</td>
<td>16 (64.0)</td>
</tr>
<tr>
<td>95% CI for response</td>
<td>[32.5, 63.3]</td>
<td>[42.5, 82.0]</td>
</tr>
</tbody>
</table>

* MMR, BCR-ABL/ABL ≤0.1% IS

Among the 21 resistant or intolerant CML patients who were in MMR at any time on treatment, the median time to first MMR was 2.76 months (95% CI: 0.03, 5.55). For the 17 newly diagnosed CML patients who achieved MMR, the median time to first MMR was 5.55 months (95% CI: 5.52, 5.75).

The magnitude of molecular response achieved is presented in Table 28.

Table 29  Proportions of patients who had best BCR-ABL ratio category of MR4.0 and MR4.5*

<table>
<thead>
<tr>
<th></th>
<th>Resistant or intolerant CML patients N=44</th>
<th>Newly diagnosed CML patients N=25</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR4.0 (BCR-ABL/ABL ≤0.01% IS)</td>
<td>5 (11.4)</td>
<td>8 (32.0)</td>
</tr>
<tr>
<td>MR4.5 (BCR-ABL/ABL ≤0.0032% IS)</td>
<td>2 (4.5)</td>
<td>7 (28.0)</td>
</tr>
</tbody>
</table>

* by the cut-off date

None of the 21 resistant or intolerant CML patients who were in MMR on treatment, had confirmed loss of MMR. Among the 17 newly diagnosed CML patients who achieved MMR, one
patient had confirmed loss of MMR (the patient lost CHR due to an increase in basophil count, however, did not progress to AP/BC).

One resistant or intolerant CML patient progressed to AP/BC after about 10 months on treatment.

**DETAILED PHARMACOLOGY**

**Animal Pharmacodynamics**

Nilotinib has been evaluated in preclinical studies as either the free-base (AMN107-NX) or as a mono-hydrochloride salt (AMN107-AA), and has been developed as an oral formulation of the mono-hydrochloride salt. Both AMN107-NX and AMN107-AA are absorbed following oral administration to animals, and the compound is tolerated at doses showing efficacy in murine myeloproliferative disease models.

*In vitro* and *in vivo* pharmacology studies have been carried out to characterize and define the activity and selectivity of nilotinib (AMN107-NX). For *in vitro* studies both human CML cell lines and murine hematopoietic cells lines have been employed to characterize the antileukemic properties of the compound, and the latter cells have been employed for *in vivo* efficacy studies with nilotinib (both AMN107-NX and AMN107-AA) in mice. To assess selectivity, nilotinib (AMN107-NX) was evaluated for effects on kinase autophosphorylation and cell viability, using either engineered murine Ba/F3 cells, whose survival is dependent on the expression of constitutively activated (oncogenic) kinases, or cancer cell lines expressing the appropriate kinase.

**Animal Safety pharmacology**

Safety pharmacology studies were conducted to assess the safety of nilotinib in particular organ systems.

**CNS safety pharmacology**

The interactions of nilotinib has been evaluated in a panel of 79 *in vitro* binding assays for potential effects on G-protein coupled receptors, cell transporters, ion channels, nuclear receptors and enzymes. No significant effects on ligand-binding were seen at concentrations < 4.0 µM, other than for the human adenosine 3 receptor (IC$_{50}$ values 2.4 and 4.2 µM) and the human adenosine transporter (IC$_{50}$ values 0.9 and 3.5 µM).

Oral administration of nilotinib at doses up to 300 mg/kg to rats demonstrated no effects on CNS.

**Respiratory effects**

Oral administration of nilotinib at doses up to 300 mg/kg to rats demonstrated no effect on respiratory rate, tidal volume or minute volume.
**Cardiovascular effects**

A variety of *in vitro* and *in vivo* studies were conducted to explore possible cardiovascular effects of nilotinib. *In vitro* studies with BJA873 (the nilotinib metabolite, P36.5) were also performed.

*In vitro* cardiac safety studies demonstrated a preclinical signal for QT prolongation. No effects were seen in ECG measurements in dogs or monkeys treated up to 39 weeks or in a special telemetry study in dogs. In neonatal rat ventricular myocytes (NRVM) nilotinib (≥ 3.7 µM) increased the ratio of XBP1 mRNA spliced/un-spliced, an endoplasmic reticulum stress marker, but a reduction in cellular ATP content in NRVM was observed at a concentration of ≥11 µM. Nilotinib produced increases in heart weights and/or left ventricular mass in rats at 40 mg/kg and 80 mg/kg for 4 weeks treatment without histopathological or structural changes.

**Animal pharmacokinetics**

The program of nonclinical pharmacokinetics for nilotinib consisted of radiolabeled ADME studies in the species used for chronic toxicity testing (rat and monkey) as well as in mouse, rabbit, and human. Both oral and intravenous dosing routes were evaluated in all species except human (oral dosing only) to allow estimates of absorption and bioavailability to be made. Additional information obtained from the ADME studies included pharmacokinetic parameters of parent drug and total radioactivity, routes and rates of excretion, metabolic pathways, and mass balance. Nilotinib tissue distribution studies were performed in pigmented and non-pigmented rats. The placenta transfer of nilotinib was also investigated in pregnant rats and rabbits. The evaluation of milk excretion of nilotinib was performed in rats. *In vitro* studies with nilotinib were performed to assess blood-plasma distribution, protein binding, phenotyping of enzymes responsible for metabolism, enzyme inhibition and induction, and interactions with drug transporters.

Nilotinib is moderately absorbed in all species tested including human, with relatively high protein binding that is comparable across species. A decrease in the α-acid glycoprotein concentration may, in theory, decrease nilotinib plasma protein binding. However, this effect would be limited due to the significant binding to serum albumin. Nilotinib and/or its metabolites was mainly distributed to adrenal cortex, liver, uveal tract, and small intestine while it showed minimal brain and testis penetration which was consistent with the lack of any toxic effects being observed in these organs. Nilotinib and/or its metabolites showed some passage to the fetus which may account for the incidence of embryolethal and embryotoxicity.

In general, all of the major metabolic pathways observed in humans were also observed in the toxicological test species (mouse, rat, rabbit, and monkey).

Excretion occurred almost exclusively through the fecal route with a minor renal elimination in all species, especially in human. Liver function and drug-drug interactions (enzymes or Pgp) in the liver may affect the elimination of nilotinib.

*In vitro* cytochrome P450 phenotyping experiments indicated that CYP3A4 should be the main enzyme contributing to the oxidative metabolism of nilotinib *in vivo*. Accordingly, a clinical
drug-drug interaction study showed that the metabolism of nilotinib could be reduced by co-administration of the CYP3A4 inhibitor, ketoconazole.

*In vitro* enzyme inhibition studies performed in human liver microsomes revealed that nilotinib could act as an inhibitor of CYP2C8, CYP2C9, CYP2D6, and CYP3A4/5 activity in the clinic and possibly, but less likely, CYP2C19. Nilotinib displayed no potential for time-dependent inhibition (i.e., no mechanism-based inactivation) of any of these enzymes.

Experiments examining the effect of increasing concentrations of nilotinib on bilirubin and estradiol glucuronidation activity suggest that nilotinib could inhibit the activity of UGT1A1 in the clinic. Enzyme induction studies indicate that nilotinib can be considered to be an *in vitro* inducer of CYP2B6, CYP2C8, and CYP2C9 activities (and possibly, CYP3A4 as well). Nilotinib was also found to be a substrate (efflux ratios $\approx 4$ at a nilotinib concentration of 6 $\mu$M) for the P-gp transporter as well as a possible inhibitor of P-gp in the clinic.

Exposures were generally proportional to the dose in mice, rats, and rabbits but underproportional in dogs, monkeys, and human. There was no clear evidence of gender differences in the exposure for mice, monkeys and dogs, while for the rat, females showed somewhat higher exposure than males. No clear evidence of accumulation for rats and dogs was observed, while the monkey showed moderate accumulation.

**TOXICOLOGY**

Nilotinib has been evaluated in single dose toxicity, repeated dose toxicity, genotoxicity, reproductive toxicity, phototoxicity, carcinogenicity (rat and mice) studies.

Repeat-dose toxicity studies were conducted in rodents and non-rodents up to nine months in duration. Nilotinib was generally well tolerated and no toxicities prohibitive for use in humans were identified. The rat and cynomolgus monkey were selected as the rodent and non-rodent species for chronic toxicity testing as both species are used routinely as animal models in toxicity evaluations. All of the major metabolic pathways observed in humans were also observed in the toxicological test species (mouse, rat, rabbit, and monkey). Accordingly, all of the metabolites identified in humans were also detected in one or more of the animal species tested, with the exception of two minor fecal metabolites that accounted for 0.62% and 1.2% of the dose, respectively. There were no glutathione or cysteine-related adducts indicative of reactive metabolite formation detected in any of the species.

**Single oral dose toxicity study**

No single dose oral toxicity studies were performed.

**Single-dose intravenous toxicity study**

Nilotinib administered to rats at a single intravenous dose of 9 mg/kg did not induce any toxicologically relevant changes attributable to nilotinib and therefore this dose was considered to be the No-Observed-Adverse-Effect-Level (NOAEL).
Potentially vehicle related lesions were observed after the 14-day recovery period. Several animals which received vehicle alone or together with test item showed minimal acute or subacute focal necrosis in the brain. The distribution was considered consistent with ischemic/hypoxic changes, probably as a result of the volume of drug solution applied. No lesions were observed in animals sacrificed one day after the administration.

**Repeated dose toxicity**

Repeated dose toxicity studies in mice, rats, dogs and cynomolgus monkeys were conducted as indicated in Table 30 below. The doses presented in this section are expressed in terms of the free base.

**Table 30**  
**Repeated dose toxicity studies**

<table>
<thead>
<tr>
<th>Species (strain)</th>
<th>Study duration</th>
<th>Route of administration</th>
<th>Dose (mg/kg/day)</th>
<th>Gender and no of animals per group</th>
<th>Study Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse (OF1) non GLP</td>
<td>2-week tolerability</td>
<td>oral (gavage)</td>
<td>0, 50, 150, 450</td>
<td>5 m in control 6 m at 50, 150 and 450 mg/kg</td>
<td>[02R143]</td>
</tr>
<tr>
<td>Mouse [Crl:CD-1 (ICR)] non GLP</td>
<td>4-week range finding</td>
<td>oral (in feed)</td>
<td>0, 20, 60, 180</td>
<td>10 m + 10 f</td>
<td>[0580231]</td>
</tr>
<tr>
<td>Rat (Crl:Wist Han) non GLP</td>
<td>Rising dose, day 1, 3 &amp; 5</td>
<td>oral (gavage)</td>
<td>50-250-500</td>
<td>2 m + 2 f</td>
<td>[0370053]</td>
</tr>
<tr>
<td>Rat (Crl:Wist Han) non GLP</td>
<td>2-week range finding</td>
<td>oral (gavage)</td>
<td>0, 30, 100, 300</td>
<td>5 m + 5 f</td>
<td>[0370138]</td>
</tr>
<tr>
<td>Rat (Crl:Wist Han) GLP</td>
<td>4-week + 4-week recovery</td>
<td>oral (gavage)</td>
<td>0, 6, 20, 60</td>
<td>10 m + 10 f 6 m + 6 f for recovery in control and high dose groups</td>
<td>[0370146]</td>
</tr>
<tr>
<td>Rat (Crl:Wist Han) GLP</td>
<td>4-week</td>
<td>oral (gavage)</td>
<td>0, 20, 80</td>
<td>10 m + 10 f</td>
<td>[0510076]</td>
</tr>
<tr>
<td>Rat (Crl:Wist Han) IGS non GLP</td>
<td>4-week range finding</td>
<td>oral (in feed)</td>
<td>0, 20, 60, 180</td>
<td>6 m + 6 f</td>
<td>[0580230]</td>
</tr>
<tr>
<td>Rat (Crl:Wist Han) GLP</td>
<td>26-week + 4-week recovery</td>
<td>oral (gavage)</td>
<td>0, 6, 20, 60</td>
<td>20 m + 20 f 10 m + 10 f for recovery in</td>
<td>[0580158]</td>
</tr>
<tr>
<td>Animal</td>
<td>Study Design</td>
<td>Route</td>
<td>Dose</td>
<td>Gender</td>
<td>Notes</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>Dog (Beagle) non GLP</td>
<td>Rising dose, day 1, 3 &amp; 5, 4 days</td>
<td>oral (gavage)</td>
<td>100→300→600</td>
<td>1 m + 1 f</td>
<td>[0370052]</td>
</tr>
<tr>
<td>Dog (Beagle) non GLP</td>
<td>2-week range finding</td>
<td>oral (gavage)</td>
<td>0, 6, 20, 60</td>
<td>1 m + 1 f</td>
<td>[0370139]</td>
</tr>
<tr>
<td>Dog (Beagle) GLP</td>
<td>4-week + 4-week recovery</td>
<td>oral (gavage)</td>
<td>0, 5, 15, 45</td>
<td>3 m + 3 f</td>
<td>[0370147]</td>
</tr>
<tr>
<td>Monkey (cynomolgus) non GLP</td>
<td>Rising dose, day 1, 3 &amp; 6, 8 days</td>
<td>oral (gavage)</td>
<td>100→200→400</td>
<td>1 m + 1 f</td>
<td>[0470193]</td>
</tr>
<tr>
<td>Monkey (cynomolgus) non GLP</td>
<td>4-week</td>
<td>oral (gavage)</td>
<td>0, 100, 200, 400, 600</td>
<td>1 m + 1 f</td>
<td>[0570038]</td>
</tr>
<tr>
<td>Monkey (cynomolgus) GLP</td>
<td>39-week + 4-week recovery</td>
<td>oral (gavage)</td>
<td>0, 30, 200, 600</td>
<td>4 m + 4 f</td>
<td>[0580157]</td>
</tr>
</tbody>
</table>

f = female animals; m = male animals

Repeated dose toxicity studies in dogs up to 4 weeks duration and in cynomolgus monkeys up to 9 months duration, revealed the liver as the primary target organ of toxicity of nilotinib. Alterations included increased alanine aminotransferase and alkaline phosphatase activity, and histopathology findings (mainly sinusoidal cell or Kupffer cell hyperplasia/hypertrophy, bile duct hyperplasia and perportal fibrosis). In general the changes in clinical chemistry were fully reversible after a four week recovery period, the histological alterations only showed partial reversibility. Exposures at the lowest dose levels where the liver effects were seen were lower than the exposure in humans at a dose of 800 mg/day. Only minor liver alterations were seen in mice or rats treated up to 26 weeks. Although mainly reversible increases in cholesterol levels were seen in rats, dogs and monkeys, a lack of recovery in serum total cholesterol was observed in one female monkey (no evidence of recovery was apparent during the recovery duration) with a lack of reversibility of morphological liver changes in one male monkey. In the 2-year rat carcinogenicity study, the major target organ for non-neoplastic lesions was the uterus (dilatation, vascular ectasia, hyperplasia endothelial cell, inflammation and/or epithelial hyperplasia).

**Genotoxicity**
Genotoxicity studies in bacterial in vitro systems and in mammalian in vitro and in vivo systems with and without metabolic activation did not reveal any evidence for a mutagenic potential of nilotinib.

Carcinogenesis

In the 2-year rat carcinogenicity study conducted orally at TASIGNA at 5, 15, and 40 mg/kg/day, there was a non-statistically significant increased incidence of uterine hemangiosarcoma, adenocarcinoma and squamous cell carcinoma and an increase in follicular cell adenoma in the thyroid gland (barely reaching statistical significance). Given that the incidence of thyroid follicular cell adenoma and uterine adenocarcinoma were within the historical control range, the data do not clearly indicate that TASIGNA is carcinogenic in rats.

An increased mortality in female rats given nilotinib at ≥ 15 mg/kg/day for up to 104 weeks was observed, which was often associated with gross or microscopic uterine changes. Exposures (in terms of AUC) at the highest dose level were represented approximately 2x to 3x human daily steady state exposure at the nilotinib dose of 800 mg/day.

In the 26-week Tg.rasH2 mouse carcinogenicity study, in which nilotinib was administered at 30, 100 and 300 mg/kg/day, skin papillomas/carcinomas were detected at 300 mg/kg, representing approximately 30 to 40 times (based on AUC) the human exposure at the maximum approved dose of 800 mg/day (administered as 400 mg twice daily). The No-Observed-Effect-Level for the skin neoplastic lesions was 100 mg/kg/day, representing approximately 10 to 20 times the human exposure at the maximum approved dose of 800 mg/day (administered as 400 mg twice daily).

The major target organs for non-neoplastic lesions were the skin (epidermal hyperplasia), the growing teeth (degeneration/atrophy of the enamel organ of upper incisors and inflammation of the gingiva/odontogenic epithelium of incisors) and the thymus (increased incidence and/or severity of decreased lymphocytes).

Reproductive toxicity studies

Nilotinib did not induce teratogenicity, but did show embryo- and fetotoxicity at doses which also showed maternal toxicity. Increased post implantation loss was observed in both the fertility study, with treatment of both males and female rats, and in the embryotoxicity study with the treatment of female rabbits. Embryo-lethality and fetal effects (mainly decreased fetal weights, visceral and skeletal variations) in rats and increased resorption of fetuses and skeletal variations in rabbits were present in the embryotoxicity studies. Exposure to nilotinib in females at No-Observed-Adverse-Effect-Levels was generally less or equal to that in humans at 800 mg/day.

In a pre- and postnatal study, the oral administration of nilotinib to female rats from day 6 of gestation to day 21 or 22 post-partum resulted in maternal effects (reduced food consumption and lower body weight gains) and longer gestation period at 60 mg/kg. The maternal dose of 60 mg/kg was associated with decreased pup body weight and changes in some physical development parameters (the mean day for pinna unfolding, tooth eruption and eye opening was earlier). The No-Observed-Adverse-Effect-Level in maternal animals and offspring was a maternal dose of 20 mg/kg.
Phototoxicity

Nilotinib was shown to absorb light in the UV-B and UV-A range, and to be distributed into the skin showing a phototoxic potential in vitro. However, no phototoxicity has been observed in vivo. Therefore the risk that nilotinib causes photosensitization in patients is considered very low.
REFERENCES


PART III: CONSUMER INFORMATION

*TASIGNA®
(Nilotinib Capsules)

50 mg, 150 mg and 200 mg nilotinib
(as nilotinib hydrochloride monohydrate)

This leaflet is part III of a three-part "Product Monograph" published when TASIGNA® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about TASIGNA. Contact your doctor or pharmacist if you have any questions about the drug.

Read all of this leaflet carefully before you start taking this medicine.

Keep this leaflet. You may need to read it again.

ABOUT THIS MEDICATION

What the medication is used for:
TASIGNA is used to treat adults with:

- newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
- chronic phase and accelerated phase Ph+ CML who are no longer benefiting from other therapies for CML including imatinib.

TASIGNA is used to treat children and adolescents 2 years of age and older with:

- newly diagnosed Ph+ CML in chronic phase.
- chronic phase Ph+ CML who are no longer benefiting from other therapies for CML including imatinib.

What it does:
In patients with CML, a change in DNA (genetic material) triggers a signal that tells the body to produce abnormal white blood cells. TASIGNA blocks this signal to stop the production of these abnormal cells.

When it should not be used:
Do not use TASIGNA if you or your child:

- have an abnormal electrical signal of the heart (prolongation of QT interval),
- have uncorrectable low levels of potassium or magnesium,
- are allergic (hypersensitive) to nilotinib or any of the other ingredients of TASIGNA.

What the medicinal ingredient is:
Nilotinib.

What the important nonmedicinal ingredients are:
Colloidal silicon anhydrous, crospovidone, gelatin, iron oxide yellow, iron oxide red, lactose monohydrate, magnesium stearate, poloxamer, and titanium dioxide.
The 50 mg and 150 mg capsules also contain black iron oxide.

What dosage forms it comes in:
TASIGNA is supplied as a hard capsule, containing 50 mg, 150 mg or 200 mg nilotinib (as nilotinib hydrochloride monohydrate).

- The 50 mg capsules are red/yellow. A black imprint is stamped on each capsule (“NVR/ABL”).
- The 150 mg capsules are red. A black imprint is stamped on each capsule (“NVR/BCR”).
- The 200 mg capsules are light yellow. A red imprint is stamped on each capsule (“NVR/TKI”).

TASIGNA is available in monthly packs:
- The monthly pack for 50 mg capsules contains 120 capsules divided into 3 blister-cartons of 40 capsules/carton.
- The monthly pack for 150 mg and 200 mg capsules contains 112 capsules divided into 4 individual weekly blister-packs.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions:
TASIGNA should be given under the supervision of a doctor experienced in the use of anti-cancer drugs. Serious side effects with TASIGNA include:

- Sudden cardiac deaths,
- Prolongation of the QT interval (abnormal electrical signal of the heart),


Ischemic heart disease (heart disorder), ischemic, cerebrovascular events (stroke or other problems due to decreased blood flow to the brain) and peripheral arterial occlusive disease (PAOD) (problems with decreased blood flow to your leg), rare fatal cases have been reported,

• Liver toxicity (increase of liver enzymes), fatal cases have been reported,

• Pancreatitis (inflammation of the pancreas),

• Myelosuppression (decrease of the production of blood cells).

TASIGNA is not to be used in patients who have uncorrectable low levels of potassium or magnesium.

TASIGNA should only be stopped under the supervision of a doctor experienced in the treatment of patients with CML.

BEFORE using TASIGNA talk to your doctor or pharmacist if you or your child:

• have a heart disorder, or a heart rhythm disorder (or a family history of heart rhythm disorder) such as an irregular heartbeat or an abnormal electrical signal of the heart called “prolongation of the QT interval”,

• have a personal history of fainting spells,

• have a family history of sudden cardiac death at age of less than 50 years,

• are being treated with medicines that affect the heart beat (antiarrhythmics) or medicines that may have an unwanted effect on the function of the heart (QT prolongation) (see also other drugs that may interact with TASIGNA under “INTERACTIONS WITH THIS MEDICATION”),

• have electrolyte problems (e.g., low blood potassium levels) or conditions that could lead to electrolyte disturbances (e.g., vomiting, diarrhea, dehydration),

• have an eating disorder or are following a strict diet,

• have diabetes, especially with associated nerve disorders,

• had a stroke or other problems due to decreased blood flow to the brain,

• have problems with decreased blood flow to your legs,

• have liver/kidney disease,

• have had pancreatitis (inflammation of the pancreas),

• have intolerance to lactose (milk sugar) or one of the following rare hereditary diseases:
  ▪ Galactose intolerance
  ▪ Lapp lactase deficiency
  ▪ Glucose-galactose malabsorption.

This is because TASIGNA contains lactose.

• are pregnant or plan to get pregnant. TASIGNA is not recommended during pregnancy as it may harm the fetus. Women who can get pregnant must use highly effective birth control during treatment with TASIGNA and for at least 4 weeks after ending treatment,

• are a male patient and are concerned about your fertility (ability to father a child),

• are a sexually active male. Men who take TASIGNA must use highly effective birth control during treatment with TASIGNA, and for at least 4 weeks after ending treatment. Tell your doctor right away if your female partner becomes pregnant,

• are breast feeding or plan to breast feed. Women should not breast feed while taking TASIGNA and for two weeks after the last dose,

• have had a surgical procedure involving the removal of the entire stomach (total gastrectomy),

• have ever had or might now have a hepatitis B virus infection (a viral infection of the liver). This is because during treatment with TASIGNA, hepatitis B may become active again, which can be fatal in some cases. This is called hepatitis B reactivation. Your doctor will check for signs of this infection before and during treatment with TASIGNA.

TASIGNA can cause a possible life-threatening heart problem called QTc prolongation. QTc prolongation causes an irregular heart beat, which may uncommonly (0.17%) lead to sudden cardiac death. These heart rhythm disturbances are more likely in patients with risk factors, such as heart disease, or in the presence of certain interacting drugs. If you experience any symptoms of a possible heart rhythm disturbance, such as dizziness, palpitations (sensation of rapid, pounding, or irregular heart beat), fainting, or seizures, you should seek immediate medical attention.

Blood tests will also monitor the level of fatty substances (cholesterol and lipids) and sugar (glucose) in your blood.

TASIGNA is a treatment for adults, children and adolescents with CML. There is no experience with the use of TASIGNA in children below 2 years of age. The effects of treating children with TASIGNA for long periods of time are not known.

Children and adolescents may grow more slowly when taking TASIGNA. Your child’s doctor will measure their growth at regular visits.

Before and during the treatment with TASIGNA, certain blood tests will be done. These will monitor how TASIGNA is affecting your body. Electrocardiograms
(ECG) may also be done regularly. An ECG is a test that measures how well your heart is working.

TASIGNA may cause dizziness. DO NOT drive or use machines if you feel dizziness or are unable to see well while taking TASIGNA.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor or pharmacist before taking TASIGNA if you or your child are taking or have recently taken any other medicines, including medicines obtained without a prescription. This includes in particular:

- antiarrhythmics such as amiodarone, disopyramide, procaainamide, quinidine, sotalol, digoxin, ibutilide, flecainide, propafenone - used to treat irregular heart beat;
- verapamil - used to treat high blood pressure and some types of irregular heart beat;
- chloroquine, halofantrine, clarithromycin, haloperidol, moxifloxacin, methadone, bepridil, pimozide - medicines that may have an unwanted effect on the function of the heart (QT prolongation);
- laxatives, enemas, water pills, amphotericin B, high dose corticosteroids - medicines that can disturb electrolyte levels;
- chlorpromazine, droperidol, ziprasidone - used to stabilize thinking and behaviour;
- fluoxetine, citalopram, venlafaxine, tricyclic/tetracyclic antidepressants e.g. amitriptyline, imipramine, maprotiline - used to treat mood disorder;
- pentamidine – used to prevent and treat pneumocystis carinii pneumonia;
- chloroquine – used to treat malaria;
- vorinostat, sunitinib, lapatinib – used to treat cancers;
- salmeterol, formoterol – used to treat asthma;
- ketoconazole,itraconazole, voriconazole, levofoxacin, ciprofloxacin, fluconazole, erythromycin, clarithromycin, telithromycin, tacrolimus, cefazolin - used to treat infections;
- domperidone – used to treat gastrointestinal motility disorder;
- metoclopramide, prochlorperazine, ondansetron and dolasetron- used to treat nausea;
- ritonavir - an anti-HIV medicine from the class “antiproteases”;
- carbamazepine, phenobarbital, phenytoin - used to treat epilepsy;
- rifampicin - used to treat tuberculosis;
- St. John’s Wort - a herbal product (also known as Hypericum Perforatum);
- midazolam - used to relieve anxiety before surgery;
- warfarin - used to treat blood coagulation disorders (such as blood clots or thromboses);
- morphine, methadone - used to treat moderate to severe pain;
- buprenorphine- substitute treatment for opioids dependence;
- cyclosporine A- used to prevent organ transplantations rejections, and to treat autoimmune conditions;
- alfentanil and fentanyl - used to treat pain and used as a sedative before or during surgery or medical procedure;
- cyclosporine, sirolimus and tacrolimus - medicines that suppress the “self-defense” ability of the body and fight infections - commonly used to prevent the rejection of transplanted organs such as liver, heart and kidney;
- dihydroergotamine and ergotamine – used to treat dementia;
- levophthyroxine– used to treat thyroid deficiency
- statins (such as simvastatin and lovastatin)- class of drugs used to treat high level of fats in blood.

In addition, while taking TASIGNA, speak with the doctor before taking antacids (medicines against heartburn). These medications need to be taken separately from TASIGNA:

- antacids called H2 blockers which suppress the production of acid in the stomach – should be taken approximately 10 hours before and approximately 2 hours after you take TASIGNA;
- antacids such as those containing aluminum hydroxide, magnesium hydroxide and simethicone which neutralize the high acidity of the stomach – should be taken approximately 2 hours before or approximately 2 hours after you take TASIGNA.

If the patient sees other doctors while taking TASIGNA, tell them about TASIGNA use.

Do not take TASIGNA with food. Taking TASIGNA with food may increase the amount of TASIGNA in the blood, possibly to a harmful level.

Do not take any products or juices containing grapefruit, star fruit, pomegranate, Seville oranges or similar fruits while taking TASIGNA. This may increase the amount of TASIGNA in blood, possibly to a harmful level.

PROPER USE OF THIS MEDICATION
Adults:
Always take TASIGNA exactly as your doctor has told you.

Newly diagnosed Ph+ CML in chronic phase:
- **Usual daily dose 600 mg:** take two 150 mg capsules two times a day, approximately every 12 hours.
- **Reduced daily dose 400 mg:** take two 200 mg capsules once a day.

Chronic phase and accelerated phase Ph+ CML in patients who are no longer benefitting from previous treatment for CML:
- **Usual daily dose 800 mg:** take two 200 mg capsules two times a day, approximately every 12 hours.
- **Reduced daily dose 400 mg:** take two 200 mg capsules once a day.

Children and adolescents
- Always give TASIGNA to your child exactly as the doctor has told you.
- Your child’s dose will depend on their body weight and height. The doctor will calculate the correct dose to use and tell you how many capsules of TASIGNA to give to your child.
- Your child’s dose of TASIGNA may change as your child grows.

### Pediatric dosing of TASIGNA

<table>
<thead>
<tr>
<th>Total Daily Dose</th>
<th>How to take this dose</th>
<th>Morning:</th>
<th>Evening:</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mg</td>
<td>Take one 50 mg capsule twice a day</td>
<td>1 x 50 mg</td>
<td>1 x 50 mg</td>
</tr>
<tr>
<td>200 mg</td>
<td>Take two 50 mg capsules twice a day</td>
<td>2 x 50 mg</td>
<td>2 x 50 mg</td>
</tr>
<tr>
<td>300 mg</td>
<td>Take one 150 mg capsule twice a day</td>
<td>1 x 150 mg</td>
<td>1 x 150 mg</td>
</tr>
<tr>
<td>400 mg</td>
<td>Take one 200 mg capsule twice a day</td>
<td>1 x 200 mg</td>
<td>1 x 200 mg</td>
</tr>
<tr>
<td>500 mg</td>
<td>Take one 50 mg and one 200 mg capsule twice a day</td>
<td>1 x 200 mg and 1 x 50 mg</td>
<td></td>
</tr>
<tr>
<td>600 mg</td>
<td>Take two 150 mg capsules twice a day</td>
<td>2 x 150 mg</td>
<td>2 x 150 mg</td>
</tr>
<tr>
<td>700 mg</td>
<td>Take one 200 mg and one 150 mg capsule twice a day</td>
<td>1 x 200 mg and 1 x 150 mg</td>
<td>1 x 200 mg and 1 x 150 mg</td>
</tr>
<tr>
<td>800 mg</td>
<td>Take two 200 mg capsules twice a day</td>
<td>2 x 200 mg</td>
<td>2 x 200 mg</td>
</tr>
</tbody>
</table>

Swallow capsules whole with water on an empty stomach. Do not consume any food for at least 2 hours before the dose is taken and for at least 1 hour after the dose is taken. Do not open the capsules.

If capsules cannot be swallowed:
- **Open** the capsules
- **Mix** the content of each capsule in one teaspoon of applesauce (pureed apple)
  - Use **only one single teaspoon** of applesauce (not more).
  - Use **only applesauce** (no other food).

Swallow the mixture immediately.

**Treatment Discontinuation:**
The doctor may lower the dose, stop the treatment for a short time or discuss the option of stopping treatment completely. This may be based on a specific blood test result or if you or your child feels unwell.

If treatment with TASIGNA is stopped, the doctor will continue to carefully monitor your CML or that of your child. The doctor may tell you or your child to re-start TASIGNA if the condition requires it.

**Overdose:**

If you or your child have taken more TASIGNA than directed, or if someone else accidentally takes the capsules, contact your doctor or the nearest hospital emergency room or a local poison control centre immediately. You may be asked to show them the pack of capsules.
Missed Dose:
If a dose is missed, take the next dose as scheduled. Do not take a double dose to make up for the forgotten capsules.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

As with all medicines, TASIGNA can cause side effects. These are not all the possible side effects that may be experienced when taking TASIGNA. If any side effects not listed here are experienced, or these affect you or your child severely, tell your doctor or pharmacist.

- fatigue;
- weakness;
- muscle pain;
- itching;
- hair loss;
- upper respiratory tract infections;
- dyspepsia (digestion problems), eating disorder (anorexia), disturbed sense of taste;
- skin reddening;
- insomnia, depression, anxiety.

Call your doctor as soon as possible if you faint (loss of consciousness) or have an irregular heartbeat while taking TASIGNA as these may be due to a serious heart condition.

If you are the caregiver of a child who is being treated with TASIGNA, tell the doctor if any of the above conditions apply to your child.

<table>
<thead>
<tr>
<th>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency / Symptom / effect</td>
</tr>
<tr>
<td>------------------------------</td>
</tr>
<tr>
<td>Only if severe</td>
</tr>
<tr>
<td>Common</td>
</tr>
<tr>
<td>Parasthesia:</td>
</tr>
<tr>
<td>Heart Disorders:</td>
</tr>
<tr>
<td>Heart failure:</td>
</tr>
<tr>
<td>Prolongation of QT interval:</td>
</tr>
<tr>
<td>Abdominal pain</td>
</tr>
<tr>
<td>Fever</td>
</tr>
<tr>
<td>Lung Disorders:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Very Common or Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes in blood test results:</td>
</tr>
<tr>
<td>High levels of</td>
</tr>
</tbody>
</table>
### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Frequency / Symptom / effect</th>
<th>Talk with your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
</tbody>
</table>

#### Inflammation of the pancreas (pancreatitis):
- Severe upper (middle or left) abdominal pain

#### Growth Retardation:
- (when a child is not growing at a normal rate for their age)

#### Common or uncommon

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water retention: Rapid weight gain, swelling of hands, ankles, feet or face</td>
<td>✓</td>
</tr>
<tr>
<td>High blood sugar: Excessive thirst, high urine output, increased appetite with weight loss, tiredness</td>
<td>✓</td>
</tr>
</tbody>
</table>

#### Uncommon

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver Damage: Yellow skin and eyes, nausea, loss of appetite, dark-colored urine</td>
<td>✓</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>✓</td>
</tr>
<tr>
<td>Vomiting</td>
<td>✓</td>
</tr>
<tr>
<td>Gastrointestinal disorders: Abdominal pain, nausea, vomiting of blood, black stools, constipation, heartburn, swelling or bloating of the abdomen</td>
<td>✓</td>
</tr>
<tr>
<td>Blocked artery in leg, arm, finger or toe: pain or discomfort, weakness, or cramping in leg</td>
<td>✓</td>
</tr>
</tbody>
</table>

#### Migraine:
- Severe headache often

#### Muscles which may be due to decreased blood flow, ulcers that heal slowly or not at all and noticeable changes in color (blueness or paleness) or temperature (coolness)

#### Generally feeling unwell

#### Bone pain

#### Pain in joints

#### Urinary tract disorders:
- Difficulty and pain when passing urine, exaggerated sense of needing to urinate, blood in urine

#### Overactive thyroid gland (hyperthyroid):
- Fast heart beat, bulging eyes, weight loss, swelling at front of the neck

#### Low levels of growth hormone (growth hormone deficiency):
- Growing more slowly, short stature, weight gain especially around the body, changes in muscle mass, changes in mood, delay in start of puberty

#### Low levels of growth hormone (growth hormone deficiency):
| Uncommon or Unknown Frequency | Nervous system disorders (such as bleeding in the skull): Weakness or paralysis of limbs or face, difficulty speaking, severe headache, seeing, feeling or hearing things that are not there, loss of consciousness, confusion, disorientation, trembling | ✓ |
| Kidney disorders (including kidney failure): Thirst, dry skin, irritability, dark urine, decreased urine output | ✓ |
| Eye disorders: Blurred vision, loss of vision in eye, increased sensitivity of the eyes to light, eye pain or redness, swelling and itching of the eyelids, decreased sharpness of vision, eye irritation | ✓ |
| Skin disorders: Rash, painful red lumps, pain in joints and muscles | ✓ |
| Underactive thyroid gland | ✓ |

<table>
<thead>
<tr>
<th>Frequency / Symptom / effect</th>
<th>Talk with your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only if severe</td>
<td>In all cases</td>
<td></td>
</tr>
</tbody>
</table>

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

- **Kidney disorders (including kidney failure):** Thirst, dry skin, irritability, dark urine, decreased urine output
- **Nervous system disorders (such as bleeding in the skull):** Weakness or paralysis of limbs or face, difficulty speaking, severe headache, seeing, feeling or hearing things that are not there, loss of consciousness, confusion, disorientation, trembling
- **Eye disorders:** Blurred vision, loss of vision in eye, increased sensitivity of the eyes to light, eye pain or redness, swelling and itching of the eyelids, decreased sharpness of vision, eye irritation
- **Skin disorders:** Rash, painful red lumps, pain in joints and muscles
- **Underactive thyroid gland**

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

- **(hypothyroid):** Weight gain, tiredness, hair loss, muscle weakness, feeling cold
- **Rhabdomyolysis (breakdown of damaged muscle):** Muscle spasms, fever, red-brown urine
- **Blood clot in a vein:** Swelling and pain in one part of the body
- **Low blood pressure:** Dizziness, spinning, sensation
- **Second malignancies (such as gastric cancer, gastrointestinal stromal tumour, pancreatic carcinoma, pancreatic neuroendocrine tumour, colon cancer)**
- **Tumour lysis syndrome (the sudden, rapid death of cancer cells due to the treatment):** Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint pain
### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Frequency / Symptom / effect</th>
<th>Talk with your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only if severe</td>
<td>In all cases</td>
<td></td>
</tr>
</tbody>
</table>

- **Hepatitis B reactivation** *(a previous viral infection of the liver becomes active again):*
  - fever, skin rash, joint pain and inflammation as well as tiredness, loss of appetite, nausea, jaundice (yellowing of the skin or whites of eyes), pain in the upper right abdomen, pale stools and dark urine. Hepatitis B reactivation can be fatal in some cases

- **Severe allergic reaction:**
  - Rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing, dizziness

- **Cardiac tamponade:**
  - Anxiety, restlessness, chest pain

- **Bronchospasm:**
  - Difficulty breathing with wheezing or coughing

- **Abnormal laboratory values:**
  - Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated

- **Reported from post-marketing with Unknown Frequency**

- **Spontaneous abortions, stillbirth and fetal malformations.**

- **Facial paralysis** *(weakness and paralysis of face muscles):*
  - loss of movement on one side of the face; drooping eye, drooping corner of the mouth, difficulty closing your eye, asymmetry of face

*This is not a complete list of side effects. For any unexpected effects while taking TASIGNA, contact your doctor or pharmacist.*

### HOW TO STORE IT

- Keep out of the reach and sight of children.
- Do not use TASIGNA after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
- Store at room temperature (15-30°C).
- Store in the original package.
Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

Please consult the doctor or pharmacist with any questions or concerns you may have regarding your individual condition.

This document plus the full product monograph, prepared for health professionals can be found at: http://www.novartis.ca or by contacting the sponsor Novartis Pharmaceuticals Canada Inc., at: 1-800-363-8883

This leaflet was prepared by Novartis Pharmaceuticals Canada Inc.
385, Bouchard Blvd.
Dorval, Quebec, H9S 1A9

Last revised: November 17, 2020

TASIGNA is a registered trademark.